Identification of the Meckel syndrome gene (MKS1) exposes a novel ciliopathy by Kyttälä, Mira
Publications of the National Public Health Institute   A   5/2006   
Department of Molecular Medicine 
National Public Health Institute, Helsinki, Finland
and
Department of Human Genetics
David Geffen School of Medicine at UCLA, Los Angeles, California, USA
and
Department of Medical Genetics
University of Helsinki, Finland
Identiﬁcation of the Meckel 
Syndrome Gene (MKS1)
Exposes a Novel Ciliopathy
Mira Kyttälä
  
 
 
 
Mira Kyttälä 
I D E N T I F I C A T I O N  O F  T H E  M E C K E L  
S Y N D R O M E  G E N E  ( M K S 1 )  E X P O S E S  A  
N O V E L  C I L I O P A T H Y.  
 
 
 
 
A C A D E M I C  D I S S E R T A T I O N  
 
To be presented with the permission of the Medical Faculty, University of Helsinki, 
for public examination in the large lecture hall at the Haartman Institute, 
Haartmaninkatu 3, Helsinki, March 31st, at 12 noon 
 
 
Department of Molecular Medicine, National Public Health Institute,  
Helsinki, Finland 
and 
Department of Human Genetics, David Geffen School of Medicine at            
UCLA, Los Angeles, California, USA. 
and 
Department of Medical Genetics, University of Helsinki, Finland 
 
Helsinki 2006
 2 
 
P u b l i c a t i o n s  o f  t h e  N a t i o n a l  P u b l i c  H e a l t h  I n s t i t u t e  
K T L  A 5  /  2 0 0 6  
 
Copyright National Public Health Institute 
 
Julkaisija-Utgivare-Publisher 
Kansanterveyslaitos (KTL) 
Mannerheimintie 166 
00300 Helsinki 
Puh. vaihde (09) 474 41, telefax (09) 4744 8408 
Folkhälsoinstitutet 
Mannerheimvägen 166 
00300 Helsingfors 
Tel. växel (09) 474 41, telefax (09) 4744 8408 
National Public Health Institute 
Mannerheimintie 166 
FIN-00300 Helsinki, Finland 
Telephone +358 9 474 41, telefax +358 9 4744 8408 
ISBN 951-740-610-X  
ISSN 0359-3584  
ISBN 951-740-611-8 (pdf)  
ISSN 1458-6290 (pdf) 
Kannen kuva - cover graphic: The Mks1 gene expression in mouse embryo at 
embryonic day 15.5 (RNA in situ hybridization). 
 
Painopaikka 
Edita Prima Oy 
Helsinki 2006 
 3 
 
 
 
 
 
S u p e r v i s e d  b y  
Docent Marjo Kestilä 
National Public Health Institute  
Department of Molecular Medicine 
Helsinki, Finland  
 
Academy professor Leena Peltonen-Palotie 
                                                                                  National Public Health Institute  
Department of Molecular Medicine and  
University of Helsinki  
                                                                                 Department of Medical Genetics 
                                                                                    Helsinki, Finland 
 
 
R e v i e w e d  b y  
Docent Kirsi Huoponen 
Department of Medical Genetics 
University of Turku 
Turku, Finland 
 
Docent Elisabeth Widen 
The Finnish Genome Center  
University of Helsinki 
Helsinki, Finland 
 
 
O p p o n e n t  
Associate Professor Brendan Lee 
Department of Molecular and Human Genetics  
Baylor College of Medicine  
Houston, TX, USA and  
Department of Molecular and Human Genetics 
Howard Hughes Medical Institute 
Chevy Chase, MD, USA 
 
 
 
 
 
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family and friends. 
 
 
 
 
…In the end everything makes sense. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
Mira Kyttälä, Identification of the Meckel syndrome gene (MKS1) exposes a novel 
ciliopathy.  
Publications of the National Public Health Insitute, A5/2006, 112 Pages 
ISBN 951-740-610-X; 951-740-611-8 (pdf-version) 
ISSN 0359-3584; 1458-6290 (pdf-version) 
http://www.ktl.fi/ portal/4043 
 
 
ABSTRACT 
Meckel syndrome (MKS, MIM 249000) is an autosomal recessive developmental 
disorder causing death in utero or shortly after birth. The hallmarks of the disease 
are cystic kidney dysplasia and fibrotic changes of the liver, occipital encephalocele 
with or without hydrocephalus and polydactyly. Other anomalies frequently seen in 
the patients are incomplete development of the male genitalia, club feet and cleft lip 
or palate. The clinical picture has been well characterized in the literature while the 
molecular pathology underlying the disease has remained unclear until now.  
In this study we identified the first MKS gene by utilizing the disease 
haplotypes in Finnish MKS families linked to the MKS1 locus on chromosome 
17q23 (MKS1) locus.  Subsequently, the genetic heterogeneity of MKS was 
established in the Finnish families. Mutations in at least four different genes can 
cause MKS. These genes have been mapped to the chromosomes 17q23 (MKS1), 
11q13 (MKS2), 8q22 (MKS3) and 9q33 (MKS4). Two of these genes have been 
identified so far: The MKS1 gene (this work) and  the MKS3 gene (Smith et al., 
2006).   
The identified MKS1 gene was initially a novel human gene which is 
conserved among species. We  found three different MKS mutations, one of them 
being the Finnish founder mutation. The information available from MKS1 orthologs 
in other species convinced us that the MKS1 gene is required for normal 
ciliogenesis. Defects of the cilial system in other human diseases and model 
organisms actually cause phenotypic features similar to those seen in MKS patients. 
The MKS3 (TMEM67) gene  encodes a transmembrane protein and the gene maps to 
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the syntenic Wpk locus in the rat, which is a model with polycystic kidney disease, 
agenesis of the corpus callosum and hydrocephalus. The available information from 
these two genes suggest that MKS1 would encode a structural component of the 
centriole required for normal ciliary functions, and MKS3 would be a 
transmembrane component most likely required for normal ciliary sensory signaling. 
The MKS4 locus was localized to chromosome 9q32-33 in this study by using 
an inbred Finnish family with two affected and two healthy children. This fourth 
locus contains TRIM32 gene, which is associated to another well characterized 
human ciliopathy, Bardet Biedl syndrome (BBS). Future studies should identify the 
MKS4 gene on chromosome 9q and confirm if there are more than two genes 
causing MKS Finnish families. 
The research on critical signaling pathways in organogenesis have shown 
that both Wnt and Hedgehog pathways are dependent on functional cilia. The MKS 
gene products will serve as excellent model molecules for more detailed studies of 
the functional role of cilia in organogenesis. 
 
Keywords: MKS1, MKS2, MKS3, MKS4, developmental disorder, disease 
mutation, ciliopathy.  
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TIIVISTELMÄ 
Meckelin oireyhtymä (MKS, MIM 249000) on monioireinen sikiön vakava 
kehityshäiriö, joka johtaa kuolemaan sikiövaiheessa tai heti syntymän jälkeen. 
Taudin keskeisimmät oireet ovat munuaisten kystinen dysplasia, maksan fibroottiset 
muutokset ja keskushermostoputken sulkeutumishäiriö. Näiden oireiden kanssa 
tavataan aina postaksiaalista polydaktyliaa (pikkusormen/-varpaan puolella 
ylimääräinen sormi/varvas).   
 MKS:n on perinteisesti ajateltu kuuluvan nk. suomalaiseen tautiperintöön,  
joka koostuu 36 lähinnä väistyvästi periytyvästä taudista, jotka esiintyvät 
runsaimmin Suomessa kuin muualla maailmassa, jos lainkaan. MKS:n esiintyvyys 
on Suomessa noin yksi 9 000:sta vastasyntyneestä. Epätyypillistä on että MKS:ää on 
raportoitu esiintyvän jopa korkeammalla esiintyvyydellä muissa geneettisesti 
suhteellisen homogeenisissä väestöissä. MKS1 geeni sijaitsee kromosomin 17 
pitkässä käsivarressa q23. Useiden alueellisten kandidaattigeenien poissuljennan 
jälkeen ja uusien perheiden haplotyyppikartoituksen avulla pystyimme lopulta 
pitävästi rajaamaan kriittisen alueen, jolle sijoittuu vain viisi transkriptiä. Näiden 
sekvensointi potilaiden DNA:sta osoitti patogeenisen muutoksen ainoastaan 
tuntemattomassa transkriptissä FLJ20345 (MKS1), Noin 70% suomalaisista MKS 
perheistä edustaa kromosomin 17q23 (MKS1) valtamutaatiota (FINmajor), ja potilaat 
näissä perheissä ovat homotsygootteja tämän mutaation suhteen. Niistä perheistä 
(30%), joissa potilaat eivät ole homotsygootteja valtamutaation suhteen ei ole 
löytynyt mutaatioita potilaiden MKS1 geeniä koodittavilta alueilta. FINmajor-mutaatio 
löydettiin homotsygoottisena sairailta myös kolmesta muusta perheestä, jotka 
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edustavat ei-suomalaista valkoihoista eurooppalaista väestöä. Tämä osoittaisi, että 
suomalainen valtamutaatio on vanha muutos eurooppalaisessa geeniperimässä.   
 Tämä mutaatio on introninen 29 emäksen deleetio, josta aiheuttuu virheellinen 
geenin luenta ja tämän seurauksena potilaan transkriptistä puuttuu kokonaan yksi 
eksoni. Tästä seuraa lukukehyksen siirtymä, joka johtaa virheelliseen 
proteiinituotteeseen alkaen aminohaposta 470 polypeptidissä. Lisäksi saksalaisesta 
MKS perheestä löytyi kaksi muuta MKS1 geenin mutaatiota, jotka ovat viiden 
emäksen insertio eksonissa yksi ja emästransitio intronin yksi silmukoinnin 
donorikohdassa (engl. splice donor site). 
Geneettinen heterogeenisyys on tyypillistä MKS:lle, ja tautigeenejä onkin 
kartoitettu jo neljään eri  kohtaan genomissa: kromosomiin 17q23 (MKS1), 11q13 
(MKS2), 8q24 (MKS3) ja 9q33 (MKS4). Neljäs MKS lokus on kartoitettu 
toimestamme suomalaisessa perheessä, jossa on kaksi sairasta ja kaksi tervettä lasta. 
Lähtökohtaisesti genealogian pohjalta tiesimme, että perheen  vanhemmilla on 
yhteisiä esivanhempia arviolta 1700-luvulla. Kun perheessä taudin kytkeytyminen 
tunnettuihin MKS lokuksiin oli poissuljettu, etenimme koko genomin laajuiseen 
kartoitukseen, missä käyttämämme keskimääräinen geenimerkkietäisyys oli n. 10 
cM. Tutkimme näitä tuloksia tarkemmin genotyyppittämällä 10 K SNP geenisirun, 
jossa keskimääräinen etäisyys SNP-geenimerkkien välillä on n. 200 kb. Ainoana  
positiivisena löydöksenä näistä koko genomin laajuisista kartoituksista havaitsimme 
kromosomissa 9q32-33.1 monipiste LOD arvon 3.6,  joka nähtiin yli 5 cM 
kokoisella alueella.  Erityisen mielenkiintoiseksi  tämän löydöksen tekee seikka, että 
samalle kromosomaaliselle alueelle on kartoitettu toinen ihmisen tauti, Bardet Biedl-
oireyhtymä (BBS, MIM 209900), joka on tunnettu perinnöllinen  tauti. BBS:n 
tunnetut geenivirheet johtavat värekarvarakenteiden (cilia) toiminnallisiin vikoihin.  
 MKS1 geenin on osoitettu lajien välisen vertailevan genetiikan avulla 
kuuluvan ryhmään geenejä, jotka ovat keskeisiä kudosten värekarvarakenteille (engl. 
cilia), niiden ylläpidolle ja toiminnalle (Flagellar and basal body proteome, FABB 
proteome). Värekarvat eli ciliat ovat solu-organelleja, jotka liittyvät mm. solun 
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liikkumiseen, solusykliin ja sensoriseen solusignalointiin, ja niillä on keskeinen rooli 
solun tasopolarisuuden muodostumisessa. Lisäksi muut taudit sekä eläinmallit, 
joissa tunnetaan cilian rakenteellisia tai toiminnan kannalta keskeisiä geenivirheitä 
jakavat paljon yhteisiä piirteitä MKS:n kanssa. Myös alustavat tutkimuksemme 
MKS1:n solulokalisaatiosta tukevat MKS:n ciliopatia luonnetta. MKS geenituotteet 
tulevat mitä todennäköisimmin toimimaan tärkeinä mallimolekyyleinä näiden 
suhteellisen vähän karakterisoitujen soluorganellien toiminnassa.  
 
Avansanat: MKS, lokusheterogeenisyys, suomalainen tautiperintö, sikiön 
kehityshäiriö, kytkentäepätasapaino, tautimutaatio. 
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bp                                                                             basepair 
CEPH                                                                       Centre d'Etude du     
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mRNA   messenger RNA 
ORF   open reading frame 
PAC   P1 derived artificial chromosome 
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PAGE  polyacrylamide gel    
                                                                                 electrophoresis 
PCR   polymerase chain reaction 
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RNA   ribonucleic acid 
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SNP   single nucleotide polymorphism 
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INTRODUCTION 
Meckel syndrome (MKS) is one of the best characterized human malformation 
syndromes.  The clinical features of MKS were described for the first time in the 
literature over hundred years ago, but the molecular and cellular pathogenesis of this 
autosomal recessive developmental defect has remained obscure until now. The aim 
of this thesis work was to identify the gene underlying the disease by utilizing the 
founder effect of an isolated population. Our study was greatly aided by the 
advances of the Human genome project and we successfully identified a novel 
human gene mutated in MKS. The initial analysis of this gene (MKS1) and its gene 
product has already provided significant new knowledge about the pathogenesis of 
MKS at the molecular level. In the future the research on the MKS1 gene will 
provide more detailed information about the molecular mechanisms critical in 
normal embryonic development. This should also provide essential information in 
understanding some more common conditions with related defects.  
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REVIEW OF THE LITERATURE 
1. MECKEL SYNDROME 
1.1 History 
Meckel syndrome is one of the best characterized malformation syndromes affecting 
normal embryonic development. The clinical picture of MKS has been described in 
the literature for the first time already in 1684 by Christopher Krahe describing a 
monstrous child born in Denmark who possibly suffered from MKS (Kompanje, 
2003). In 1822 J. F. Meckel published a detailed pathological report of two siblings 
(male and female), who died with identical lethal malformations. Meckel´s clinical 
descriptions still agree with the modern diagnostic criteria.  Over hundred years later 
Gruber (1934) suggested the genetic origin of MKS because the cases were familial. 
In the 1960´s Opitz and Howe introduced the name Meckel syndrome and delineated 
the clinical and pathological features based on one observation and presented a 
thorough review of the literature (Opitz and Howe, 1969). In Finland the careful 
clinical, epidemiological and pathological studies were performed by Salonen and 
Norio which expedited the research on the molecular genetics of MKS in Finland 
(Salonen 1984; Salonen and Norio 1984). 
 
1.2 Meckel syndrome world wide 
MKS is reported world wide (Hsia et al., 1971; Mecke and Passarge, 1971; 
Moerman 1982). There are several reports of the incidences available in the 
literature, however the true extended reports of the prevelences in distinct 
populations are rare. The incidence in Northern America and Western Europe varies 
from the estimates of   
1: 3 400- 1: 140 000 newborn (Holmes, 1976; Seller 1978). The lowest incidence is 
reported from Great Britain and respectively the highest from Belgium.  In Finland 
Salonen and Norio (1984) studied a comprehensive cohort of cases and families and 
estimated the prevalence in Finland to be 1: 9 000 newborn. This means that there 
are approximately 5-7 new cases in a year. Several reports are available from 
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distinct populations throughout the world: Indonesia, Pakistan and Japan (Tan and 
Thomas, 1970; Crawfurd et al., 1978; Sugiura et al., 1996) as well as in Arabs in 
Saudi Arabia, Jews and Palestinian Arabs in Israel (Haque and Zaidi 1981; Fried, 
1973; Zlotogora, 1997).  Surprisingly high incidences have been reported in Gujarati 
Indians, 1: 1 100; Kuwaitian Bedouins, 1: 3 530 and in Belgians, 1: 3 400 (Young et 
al., 1985; Teebi et al., 1992; Moerman et al., 1982).  
 
1.3 Clinical picture 
1.3.1 Main features 
In the most typical cases MKS results in a death in couple hours after birth. In the 67 
MKS cases reported by Salonen (1984; 1986) the detected rate of spontaneous 
abortions (15.2%) is within the normal range. The survival time of 40 liveborn 
infants was under 2.5 hours. The cesarian section was performed in ten cases 
because of hydrocephaly, abnormal position or asphyctic signs of the fetus. 
Oligohydramnious was detected at birth in 30 cases including 15 cases without 
amniotic fluid. MKS can be diagnosed reliably by the ultrasound examination of the 
embryo. In most cases the pregnancies will be terminated at 10-14 weeks of 
gestation  if MKS is diagnosed.  
The main characteristic features are the CNS (central nervous system) defect 
that always appears together with cystic dysplasia of the kidneys, fibrotic changes of 
the liver and polydactyly (Fig. 1).  
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Figure 1. A fetus with MKS having the typical phenotype at 21 weeks of gestation. 
The arrows are pointing the main hallmarks: Occipital encephalocele, polydactyly 
and the massive abdomen caused by the distended cystic kidneys.  The picture is a 
courtesy from Dr. Riitta Salonen. 
 
1.3.2 Central nervous system, (CNS) 
The occipital meningo encephalocele is seen in 90% of the cases (Aleksic et al., 
1984; Paetau et al., 1985; Ahdad-Barmada and Claasen, 1990). In 10-20% of the 
patients it is accompanied with hydrocephaly.  However, the severity of the CNS 
malformation can vary from a mild partial defect of corpus callosum to a severe total 
craniorachischisis (open spinal canal) and anencephaly.   
The dysgenesis of the forebrain with the absence of the olfactory tracts and 
bulbs is frequent (Miller and Selden, 1967; Rehder and Labbe, 1981; Anderson, 
1982; Paetau et al., 1985; Ahbad-Barmada and Claasen, 1990). A microscopically 
interesting feature is the reported neuroepithelial rosettes, or as the author himself 
described the phenomenon: “peculiar ectopic neuroepithelial rosettes” (Paetau et al., 
1985). These can be interpreted as ependymal rosettes, which are mainly detected in 
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the germinal matrix region but they can also be found far from the midline of the 
brain. The neuroepithelial rosettes could reflect a defect in the neuronal proliferation 
and migration.  Similar findings are also observed in the eye: retinal dysplasia with 
rosettes of pigmented retinal epithelium (Miller and Selden, 1967; Anderson, 1982). 
 
1.3.3 Kidneys 
 One of the most consistent malformation in MKS is the enlarged kidneys (with 5-50 
fold increase in weight), that cause the bulky abdomen which is typical for an 
embryo having MKS. In most cases the enlargement involves both kidneys. The 
macroscopical cysts vary in size from several millimetres to 200 mm (Fig. 2a). 
Histologically the renal parenchyma is characterized by smaller cysts in the 
peripheral cortex with a thin zone of normal glomeruli, and thin walled, larger cysts 
in the medullary part separated by loose connective tissue (Fig. 2b and 2c) 
(Moerman et al., 1982; Rehder and Labbe, 1981; Anderson, 1982; Rapola and 
Salonen, 1985; Blankenberg, 1987). 
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Figure 2 a) Photograph of MKS kidney. The picture is a courtesy from Dr. Riitta 
Salonen. b) Histology of MKS kidney at 20+4 weeks of gestation. c) Histology of 
normal control kidney at 13 weeks of gestation.   
 
1.3.4 Liver  
Macroscopically the liver often seems normal, but can be somewhat enlarged. 
Occasionally macroscopic fibrosis and cysts of liver occur. The microscopic 
findings are detected in a histological examination exposing in all cases liver bile 
duct anomalies and fibrotic changes (“collagenous tissue”, Salonen, 1986), 
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especially in the portal areas (Fig. 3) (Moerman et al., 1982; Rehder and Labbe, 
1981; Anderson, 1982; Rapola and Salonen, 1985; Blankenberg, 1987).   
 
Figure 3. Histology of MKS liver at 20+4 weeks of gestation showing the typical 
ductal plate malformation.  
 
1.3.5 Situs inversus in MKS  
In the initial publication by Salonen (1984) three out of 67 MKS cases are reported 
with a finding of situs inversus totalis, demonstrating an elevated incidence of this 
rare condition in the MKS patients. Since MKS is screened efficiently by prenatal 
ultrasound examination, and the detected MKS pregnancies are normally terminated 
during the gestational weeks 10-14, it is possible that in the small embryo the 
abnormal organ situs has not always been detected if it is not an expected finding.  
Situs inversus is known to occur with increased frequency in diseases that 
affect the structure or the function of cilia. Good examples are human diseases like 
Kartagener syndrome (MIM 244400) and primary ciliary dyskinesia (PCD, MIM 
242650). The embryonic nodal cilia have been studied in detailed in mice, and they 
are involved in the left right situs determination and ciliary dysfunction leads to 
randomized situs formation (Supp et al., 1997; Okada et al., 1999).  
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1.3.6 Other frequent symptoms 
Epithelial branching morphogenesis is typical for most of the tissues affected in 
MKS and the pathological findings are considerably similar in different tissue types 
(Blankenberg et al., 1987). Lungs are frequently reported to be small and 
hypoplastic in patients. Rapola and Salonen (1985) reported that the weight of the 
lungs varied 20-80% from the expected in 14 recorded cases and only in one case 
the weight was within normal limits. Club feet and the ambiguous male genitalia are 
also typical features of MKS. The other variably associated malformations are: heart 
defect, cleft lip and/or palate, anomalies and tumours of the tongue, ocular 
anomalies and polysplenia. (Fried et al., 1971; Mecke and Passarge, 1971; Fraser 
and Lytwyn, 1981; Rehder and Labbe, 1981; Anderson, 1982; Moerman et al., 1982, 
Salonen 1984; Ahbad-Barmada and Claasen, 1990). 
 
1.4 Genetics of MKS  
The autosomal recessive inheritance and locus heterogeneity have been established 
in MKS (Hsia et al., 1971; Mecke and Passarge, 1971; Salonen, 1984; Roume et al., 
1997; Morgan et al., 2002).  Three genetic loci are known to be involved. These loci 
have been assigned in families representing relatively isolated populations. The 
three identified MKS loci are located on chromosomes 17q23 (MKS1, Paavola et 
al., 1995), 11q13 (MKS2, Roume et al., 1998) and 8q22 (MKS3, Morgan et al., 
2002). The MKS3 gene has recently been identified (Smith et al., 2006).  
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1.4.1 Chromosome 17q, MKS1  
The original linkage study assigned the first MKS locus to chromosome 17q21-q24 
in a genome scan of five Finnish families with two or more MKS affected siblings 
(Paavola et al., 1995).  This produced a maximum pair wise LOD score of 5.42 for 
microsatellite marker D17S1606. The initial linkage was observed over a 13 cM 
genetic region (Paavola et al., 1995).  
 
1.4.2 Chromosome 11q, MKS2 
The MKS2 locus was assigned to chromosome 11q13 in Middle Eastern and 
Northern African MKS families (Roume et al., 1998). Linkage to MKS1 locus had 
been previously excluded in these families (Roume et al., 1997). A genome wide 
scan in a total of seven consanguineous families (4 Tunisian, 1 Algerian, 1 
Senegalian and 1 Pakistani) resulted in the highest pair wise LOD score of 4.4, 
which was obtained at two marker loci: D11S906 and D11S911. The affected 
fetuses of Tunisian ancestry had the same haplotype at marker loci D11S911 and 
D11S906, suggesting a founder effect in Tunisian MKS families. 
 
 1.4.3 Chromosome 8q and MKS3 gene mutated in MKS 
The MKS3 locus was mapped in consanguineous English families originating from 
Pakistan and India. The original genome scan assigned the MKS3 locus to 
chromosome 8q24 (Morgan et al., 2002). The MKS3 (Meckelin) gene was recently 
identified and is mutated in MKS3 (Smith et al., 2006).  The MKS3 gene is located 
on 8q22, which is somewhat more proximal than the region on 8q24, which was 
originally defined by linkage (Morgan et al., 2002). 
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The TMEM67/MKS3 gene is mutated in MKS3 
The TMEM67/MKS3 gene encodes a transmembrane receptor protein, which 
mutations in the rat ortholous gene (Mks3) causes polycystic kidney disease, 
agenesis of the corpus callosum and hydrocephalus. (Smith et al., 2006).  The role of 
the MKS3 gene in ciliary functions has been hypothesized based on its topological 
similarity to the  Drosophila melanogaster FZ (Frizzled) family of receptors 
(Cadigan and Nusse, 1997; Xu et al., 1998). The Frizzled signaling in fruit fly has an 
important role in epithelial planar cell polarity (PCP) (Jenny et al., 2005). Disrupted 
PCP signaling has been implicated in Bardet Biedl syndrome (BBS) (Ross et al., 
2005) a disorder associated with primary ciliary and basal body dysfunction (Ansley 
et al., 2003; Beales 2005). Further evidence of the ciliary expression comes from the 
Caenorhabditis elegans homolog of MKS3/TMEM67 (F35D2.4) which has a 
previously described X-box motif approximately 75 bp upstream of the probable 
start codon, a characteristic of proteins found in cilia (Efimenko et al., 2005). 
 
2. THE FINNISH DISEASE HERITAGE 
2.1 Concept  
MKS belongs to the so called Finnish disease heritage (FDH). The concept of FDH 
was introduced over 30 years ago in the original publication by Norio and co-workers 
in 1973: “Hereditary diseases in Finland; A rare flora in a rare soil”. It described 10 
genetic disorders more common in Finland than elsewhere in the world. Nowadays 
total of 36 disorders are included to the FDH (table 1). In 33 of them the disease 
causing mutation has been identified in a relatively short time period. 
The genetic structure of Finnish the population is probably the most important 
factor that led to the rapid identification of the mutations in the FDH (de la Chapelle 
and Wright, 1998; Peltonen et al., 1999; Norio, 2003; www.findis.org). In addition, 
the Finnish healthcare is of high quality and available for all citizens, the common 
attitude towards research is positive, and families are willing to participate in genetic 
studies. Furthermore, the church has kept comprehensive records of the population 
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over centuries, which makes it possible to trace back families in some cases up to 
the 16th century with the help of taxation records.   
The identification of the disease mutations underlying many of the diseases in 
the FDH has revealed previously unknown biological functions of several human 
genes. The monogenic human disorders can provide detailed information about 
novel cellular mechanisms affecting both health and disease. This information can 
be exploited in medicine in understanding related conditions, some being common 
in complex traits. 
 
Table 1.  The 36 diseases belonging to the Finnish disease heritage (FDH). In 33 of 
them the disease mutation has been identified. In most of the diseases the patients 
are homozygous for the same major (founder) mutation. The diseases are presented 
below in the chronological order of the identification of the gene defect.  
Gene defect is identified, disease,      
MIM number Defective protein product Reference for the Finnish mutation 
HYPERORNITHINEMIA WITH 
GYRATE ATROPHY OF CHOROID 
AND RETINA, (HOGA), 258870 
Ornithine ketoacid 
aminotransferase, (OAT) Mitchell et al., 1989 
MERETOJA TYPE AMYLOIDOSIS, 
(FAF), 105120, dominant Gelsolin (GSN) Levy et al., 1990; Maury et al., 1990 
ASPARTYLGLUCOSAMINURIA 
 (AGU), 208400 
Aspartyliglucosaminidase, 
(AGA) Ikonen et al., 1991 
CHOROIDEREMIA, (CHM), 303100, 
X linked, Recessive Rab-protein, (REP1) Sankila et al., 1992 
HYPERGLYCINEMIA, 
NONKETOTIC, (NKH), 605899 
Glycine decarboxylase, 
(GLDC) Kure et al., 1992 
DIASTROPHIC DYSPLASIA, (DTD) 
222600  
Diastrofic dysplasia sulfate 
carrier, (DTDST) Hästbacka et al., 1994 
CEROID LIPOFUSCINOSIS, 
NEURONAL 1, INFANTILE, 256730 
palmitoyl-protein 
thioesterase 1, (PPT) Vesa et al., 1995 
NEURONAL CEROID 
LIPOFUSCINOSIS, JUVENILE 
TYPE, (JINCL), 204200 
CLN3-protein The international Batten disease consortium 
OVARIAN DYSGENESIS, 
HYPERGONADOTROPIC, (ODG1), 
233300 
FSH-receptor, (FSHR) Aittomäki et al., 1995 
CHLORIDE DIARRHEA, FAMILIAL, 
(CLD), 214700 DRA-protein Höglund et al., 1996 
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PROGRESSIVE MYOCLONIC 
EPILEPSY, (PME1), 254800 Cystatin B, (CSTB) 
Pennacchio et al., 1996, Virtaneva et 
al., 1997 
 AUTOIMMUNE 
POLYENDOCRINOPATHY 
SYNDROME, (APECED), 240300 
Autoimmune regulator 
AIRE-protein 
Nagamine et al., 1997; The Finnish 
German APECED consortium,1997 
FINNISH CONGENITAL 
NEPHROSIS, (CNF), 256300 Nephrin Kestilä et al., 1998 
NEURONAL CEROID 
LIPOFUSCINOSIS, FINNISH 
VARIANT, LATE INFANTILE, 
(vLINCL),256731 
CLN5-protein Savukoski et al., 1998 
RETINOSCHISIS, 312700 (X linked 
recessive)  XLRS1-protein The retinoschisis consortium, 1998 
LYSINURIC PROTEIN 
INTOLERANCE, (LPI), 222700 SLC7A7-protein 
Torrents et al., 1999; Borsani et al., 
1999 
MEGALOBLASTIC ANEMIA 1,  
(SMB12), 261100 Cubilin protein (CUBN) Aminoff et al., 1999 
NORTHERN EPILEPSY, (EPMR), 
600143 CLN8-protein Ranta et al., 1999 
SIALURIA, FINNISH TYPE, 604369 SLC17A5-protein Verheijen et al., 1999 
CORNEA PLANA 2, (CNA2), 217300 KERA-protein Pellegata et al., 2000 
MULIBREY NANISM, 253250 TRIM37-protein Avela et al., 2000 
NASU-HAKOLA DISEASE, 
(PLOSL), 221770 
TYRO protein tyrosine 
kinase-binding protein 
(TYROBP)  
Paloneva et al., 2000 
CARTILAGE-HAIR HYPOPLASIA, 
(CHH), 250250 
RNA-processing 
endoribonuclease (RNRP) Ridanpää et al., 2001 
USHER SYNDROME, TYPE III, 
276902 USH3A-protein Joensuu et al., 2001 
TIBIAL MUSCULAR DYSTROPHY 
(TMD), 600334, dominant Titin (TTN) Hackman et al., 2002 
COHEN SYNDROME, 216550 COH1-protein Kolehmainen et al., 2003 
GRACILE SYNDROME, 603358 BCS1L-protein Visapää et al., 2003 
RAPADILINO SYNDROME, 266280 REQL4-helicase Siitonen et al., 2003 
MUSCLE-EYE-BRAIN DISEASE, 
(MEB), 253280 POMGnT1 Diesen et al., 2004  
HYDROLETHALUS SYNDROME, 
236680 HYLS1-protein Mee et al., 2005 
INFANTILE-ONSET 
SPINOCEREBELLAR ATAXIA; 
IOSCA, 271245              
Twinkle  Nikali et al., 2005 
LACTASE DEFICIENCY, 
CONGENITAL, (CLD), 223000 Lactase Kuokkanen et al., 2005 
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MECKEL SYNDROME, (MKS1), 
249000         MKS1 protein 
Kyttälä et al., 2006 (original 
publication III) 
The chromosomal locus of the gene 
has been assigned, disease, MIM 
number 
Chromosomal locus   
LETHAL CONGENITAL 
CONTRACTURE SYNDROME 1, 
(LCCS), 253310 
9q Mäkelä-Bengs et al., 1998 
The chromosomal location of the 
defect gene is not known, disease, 
MIM number 
  Reference  
PEHO SYNDROME, 260565  Salonen et al., 1991 
LETHAL ARTHROGRYPOSIS WITH 
ANTERIOR HORN CELL DISEASE, 
(LAAHD) 
 Vuopala et al., 1995 
 
2.2 Inhabitation of Finland and founder effect  
One theory of the inhabitation of Finland is called the dual theory and it is supported by 
studies of the Y chromosomal haplotypes (Kittles et al., 1998; Lahermo et al, 1999). 
According to this theory there have been two important groups of settlers (Fig. 4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The two important migrations to Finland according to the dual theory: The  
first settlers came 4000 years ago from South Russia, and the second group 2000 
years ago from central Europe (Peltonen et al., 1999). 
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The assumption is that the first inhabitants notably affecting to the gene pool came to 
Finland already 4000 years ago from the east (Norio 1981, Eriksson 1973, Peltonen et 
al. 1999). The second migration some 2000 years ago has still at the present day the 
most impact on the Finnish gene pool (Nevanlinna 1972, de la Chapelle 1993, 
Peltonen et al. 1999). The mitochondrial DNA (mDNA) and nuclear DNA variations 
confirm the European origin of the majority of the gene variations in Finland (Cavalli-
Sforza and Piazza 1993, Sajantila and Pääbö 1995, Lahermo et al., 1996, Sajantila et 
al., 1996, Laan and Pääbö 1997, Torroni et al., 1998). Since there is no explicit 
evidence of two major immigration waves, it is most probable that the immigration 
has occurred more gradually in small groups (Peltonen at al., 1999).  
The original founder population was small and it has been estimated that the 
population size was 50 000 people in the 12th century, but it expanded and spread to 
the country following the coastal lines while the inland remained virtually 
unpopulated.  In the beginning of the 16th century the population size of Finland was 
approximated to be 250 000 concentrating mainly on the coastal parts of the country. 
The Swedish king Gustavus of Wasa/Vasa promoted the inhabitation of the central 
and eastern parts of Finland in 16th century by providing taxation relieves for people 
moving further to the inland. This movement established the late settlement region 
in Finland (Fig. 5).  
 
 31 
 
Figure 5.The inhabitation of Finland. The early settlement region follows the 
coastal line. The late settlement region was formed by the internal migration in the 
16th century (Peltonen et al., 1999). 
 
The villages in the late settlement region originating from a small area of 
Southeastern Finland (South Savo) remained stable for centuries because of the 
relatively long geographical distances and low population density enabling the 
formation of genetic subisolates. This as well as wars, epidemics and famines 
created significant population bottlenecks. The Finnish population has expanded to 
5.3 million in just about three centuries from approximately 250 000 inhabitants.  
The rare disease alleles were enriched in the subisolates and to the whole population. 
The unique gene pool was moulded by different bottleneck effects in the small 
founder populations over centuries. Despite the industrialization and the population 
migration from rural areas to urban regions, the subpopulations particularly in the 
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late settlement areas have remained unmixed (de la Chapelle 1993; Peltonen et al., 
1999; Varilo 1999; Norio 2003). 
Many disorders, which are common elsewhere in the world, such as cystic 
fibrosis (incidence 1: 2 500 in Western Europe) are uncommon in Finland. On the 
other hand, there are many diseases in FDH which have been found only in Finland, 
like the variant form of late infantile neuronal ceroid lipofuscinosis (vLINCL) and 
Northern epilepsy (EPMR). Genetic drift also influences other more common 
monogenic diseases like familial hypercholesterolemia (FH), in which only two 
founder mutations are responsible for most of the cases among Finns (Aalto-Setälä 
et al., 1989; Koivisto et al., 1992). For many of the diseases belonging to FDH the 
birthplaces of the patients´ grandparents reflect the historical population migration 
(Varilo 1999; Norio 2000). The distribution of the grandparental birthplaces can be 
utilized in categorizing the diseases by the estimated age of the founder mutation.  
In approximately half of the diseases belonging to the FDH the grandparents´ 
birthplaces cluster to the regions of the late settlement (Norio, 2000), suggesting that 
the disease mutations have been spread during the inhabitation of central and eastern 
parts of the country in the 16th century. These mutations were introduced to the 
population some 30-40 generations ago (Varilo 1999).   
Another group of diseases is composed of those which are the most common 
in FDH: AGU, INCL, PME, JNCL and CNF. The prevalence of these disorders has 
been estimated to be 1: 8 000- 1: 19 000 and grandparental birthplaces are 
distributed evenly through out the country; however some denser regions can be 
detected on the late settlement regions. This indicates that the mutations have been 
introduced to the population earlier, approximately 80-120 generations ago 
(Peltonen 1995, Varilo 1999). vLINCL and EPMR are the youngest diseases in 
FDH, and the ancestral birthplaces can be seen only in a small, very restricted region 
on the map (Varilo et al. 1996, Norio 2000). In vLINCL families the grandparental 
birthplaces are geographically densely located in the Southern Ostrobotnia region on 
the West coast and the significant LD can be detected across 11 cM genetic region 
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thus supporting the young age of the mutation in Finland. EPMR can also be 
geographically positioned to the Nortwestern part of the country to a small region 
based on the grandparental birthplaces. The length of significant LD in the EPMR 
disease chromosomes is 10 cM is congruent with the hypothesis of a recent mutation 
(approximately 20-30 generations) (Varilo, 1999).   
 
3. DISEASE GENE IDENTIFICATION 
3.1 Main strategies 
There are several strategies to identify human disease genes. Probably the most 
important of them are the functional cloning, candidate gene analysis and positional 
cloning. In most cases it is beneficial to use a combination of the strategies.   
The functional cloning is the oldest approach to clone a disease gene. It was 
the only possible method to identify disease genes before there were genetic maps 
available from the human genome. In this strategy the defective protein product is 
first isolated and its peptide sequence will indicate the corresponding gene. The 
identification of Haemophilia A gene is an example wher this strategy was used 
(Gitschier et al., 1984).  
The candidate gene analysis requires knowledge about the molecular level 
pathogenesis of the disease. This information may be available from functional 
studies in humans or animal models. Mutations can be screened directly from the 
candidate gene in the patients. Many times this strategy is not successful alone 
without positional cloning (positional candidate gene approach).   
  The human genome maps have enabled the positional cloning approach. 
This strategy depends fully on suitable family material. This approach is most 
successful when families represent isolated populations with one founder mutation. 
In this strategy the defective gene is identified by first assigning its chromosomal 
location with classic linkage mapping. No functional information about the gene is 
required. This method is sensitive to misdiagnosis, also locus heterogeneity in the 
family material can substantially hamper the mapping effort. The linked 
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chromosomal region can be further fine mapped by utilizing linkage disequilibrium 
(LD) in the disease chromosomes. By utilizing the LD and haplotype mapping the 
critical chromosomal region can be greatly reduced from that originally detected by 
linkage. Linkage is typically seen in a vast chromosomal region spanning across 
several cM region. A combination of positional cloning and candidate gene analysis 
(positional candidate gene analysis) is at the present time probably the most rational 
approach for the disease gene identification with the growing knowledge of the 
function of the human genome. After assignment of the gene locus the regional 
candidates can be evaluated based on the information of their known functions and 
their tissue expression profiles. 
 
3.2 Human genome project 
The sequence of the 3 billion base pairs human genome has been available since 
2003, when the International Human Genome Sequencing Consortium completed 
this gigantic sequencing project (Collins et al., 2003).  
 The development of the research on the human genome from the structure of 
DNA to the finished genomic sequence has proceeded enormously just in fifty years 
(Watson and Crick, 1953; Collins et al., 2003).  At the very early stage leading to the 
human genome sequencing project a YAC contig map was available which covered 
approximately 75% of the genome (Chumakov et al., 1992). This map was soon 
complemented with STS based physical maps (Hudson et al., 1995), which were 
achieved in part by mapping whole genome radiation panels. The human genome 
mapping has evolved in only two decades from the genetic maps based on RFLPs 
(restricted fragment length polymorphism) to the first high resolution maps based on 
microsatellite markers (Weissenbach et al., 1992), and finally to the finished human 
sequence.  
 Since then, the HGP has completed sequencing of a large amount of model 
organisms (http://www.ncbi.nlm.nih.gov/genomes/static/gpstat.html). Results from 
the various genome sequencing projects have carried the biomedical research into 
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the genomic era that utilize the gene conservation among species and develop the 
ultimate tools for gene mapping in form of high-throughput SNP based techniques.  
 
3.2.1 Comparative genomics 
Comparative genomics involves analysis of two or more genomes to identify the 
extent of similarity of various features, or large scale screening of the genomes to 
identify sequences present in another genome.   
 Comparative genomics can be utilized to study evolutionary relationships of 
different species. This can be further employed to recognize genes behind in specific 
cellular machineries or functions, which are known to be present/absent in the 
species that are compared. The comparisons of different complex genomes also 
enable also identification of gene coding regions as well as potential regulatory 
regions.  An analysis of the of conserved regulatory regions showed that for most of 
them (81%)  there is more than 50% sequence similarity between human and mouse, 
which is significantly higher than seen in average non-coding intronic sequence (Liu 
et al.,  2004). 
   
3.3 Linkage analysis 
Polymorphisms are normal sequence variations in the genome, and can be used as 
genetic markers in linking a disease to a certain chromosomal region. The closer the 
marker is to the disease gene the less likely a meiotic recombination has occurred 
between the two (disease and polymorphism) and hence they are more likely to be 
inherited together. The distinction between a polymorphism and a rare variant is that 
the latter one occurs in a frequency less than 1% in the population. 
 The first generation polymorphic genetic markers were RFLPs. Later the PCR 
technology made the microsatellite markers as a standard tools for linkage analysis. 
These are most often di -, tri - or tetra nucleotide repeats. The advantage of the 
multiallelic microsatellite markers is that they are normally more informative in 
genetic analyses than the SNP markers. However, the mutation rate is approximately 
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10-3-10-4 per generation for repeat markers (microsatellites), which is much higher 
than for SNPs (10-8 or less) (Drake et al., 1998).  The lower mutation rate makes 
SNPs more optimal for analyses where the cosegregation of a marker allele and 
disease is monitored for many generations (Kruglyak., 1997). There are nearly 1.4 
million SNPs in human genome and some 9 million of them have been identified as 
a result of the HGP project.  
 In order to perform linkage analysis the first requirement is to establish 
genotypes for the individuals in the study sample. The analysis follows the segregation 
of the condition and marker alleles at consecutive loci. The interpretation of the 
genotype data requires statistical means and the basis of the statistics is the formula 
developed by N.E. Morton (1955), which measures the strength of linkage in units of 
logarithm of the odds (LOD score, Z). This can be written: 
 
(1) Z(Θ)=log10 L(Θ)/L(0.5) 
Θ stands for recombination fraction between two loci where the LOD score 
peaks. Θ≥0.5 indicates that there is no linkage between loci. In logarithmic scale 
the definition for statistically significant linkage is LOD score ≥3.0 for human 
disorders with classic mendelian inheritance.  
 
 In most cases the initial linkage can be detected over a large chromosomal 
region. This resolution is not sufficient for efficient candidate gene study unless 
there are some functionally obvious candidates. In most cases the chromosomal 
region observed with the initial linkage analysis needs to get narrowed down.  
 
3.3.1 Linkage disequilibrium, LD 
Linkage disequilibrium is the non random association of alleles at different loci on 
chromosomes with frequencies higher than expected from the random combinations 
of their frequencies in the population. Several measures are available for quantifying 
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this phenomenon. λ, D´ and r2 are frequently used parameters to measure the  
amount of LD (Terwilliger, 1995; Zondervan and Cardon, 2004).  
The fundamental idea of utilizing linkage disequilibrium and haplotype 
mapping in gene mapping is that the affected individuals have inherited the gene 
defect underlying the disease from the same ancestral relative (founder) who has 
introduced the mutation to the population. As a results the genetic region in the 
vicinity of the mutation is identical in all the affected individuals carrying the same 
founder mutation in their chromosomes i.e. the mutation and the marker alleles are 
in linkage disequilibrium (LD) (Fig. 6). The length of LD reflects the mutation age 
(number of generations since the mutation was introduced to the population).  The 
mutation age can be mathematically estimated by using the Luria Delbruck based 
algorithm (Hästbacka et al. 1992).  
Isolated populations with relatively small amount of founders have been 
especially useful in isolating genes in Mendelian disorders due to the reduced 
genetic heterogeneity (Peltonen, 1999) and often the disease causing mutation is in 
complete LD with regional genetic marker(s).  
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Figure 6. The principle of LD. The black chromosome represents the original 
ancestral chromosome carrying the disease mutation. After ten generations (n=10) 
the recombinations have narrowed the chromosomal region around the mutation. 
After 50 generations (n=50) there is only a relatively short chromosomal region  in 
the closest surrounding area of the mutation originating from the ancestral disease 
chromosome.  
 
3.3.2 Haplotype mapping 
In homogenic and isolated populations patients with a rare genetic disorder are likely 
to be remotely related.  The haplotype conservation of disease chromosomes over a 
large chromosomal region confirms that they are identical by descent. Haplotype 
mapping can be utilized after the disease locus has been fine-mapped and where the 
analysis of the recombination sites in disease chromosomes has enabled significant 
reduction in the size of the critical chromosomal region.  A good example of 
restriction of the critical DNA region based on the shared haplotype is from EPM1 
(Progressive myoclonus epilepsy). The haplotype shared by affected individuals 
restricted the EPM1 critical chromosomal region to 176 kb (Lehesjoki et al., 1993). 
Disease 
mutation
The original disease
chromosome from the 
common founder
n=5
n=10
n=50
n = number of generations elapsed since 
the mutation has appeared
to the original founder chromosome
The chromosomal region 
from the original disease 
chromosome
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3.3.3 Homozygosity mapping  
In rare recessive diseases the affected children of consanguineous parents have 
inherited two identical defective gene copies from a common ancestor. As a result 
the affected individuals share the same homozygous alleles near the disease 
mutation (Smith, 1953). The approach, in which shared homozygous disease 
haplotypes resulting from consanguineous matings are utilized in disease locus 
identification, is called homozygosity mapping (Lander and Botstein, 1987). 
 
3.3.4 Identification of a disease mutation  
The interpretation of observed sequence variants in the patients´ DNA and their 
putative role in disease pathogenesis is critical. Mutations causing frameshift 
alterations in the transcript or premature stop codons (nonsense mutations) 
significantly alter the gene product and make the evaluation of the disease causing 
mutations normally less problematic than in cases where the putative disease 
causing mutation changes only one amino acid to another (missense mutation).  In 
the latter case the pathogenicity of the suspected disease mutation has to be tested. 
This can be done by utilizing the gene conservation between species since most 
often the disease causing mutation alter a conserved functional domains in the gene 
products. The mutation may change the stability of the polypeptide, which can be 
experimentally studied by comparing the stability of the mutated gene product to a 
normal control. Another important tool to analyse the potential disease mutation is 
to establish experimentally its carrier frequency in the population, which should not 
exceed the estimated carrier frequency. Even if the experimental tests would support 
the pathogenic role of the missense mutation the final proof of its causative role 
comes from studies in a model organism, where the missense mutation produces a 
pathogenic phenotype. However, in some cases species may have evolved 
differently and  complementing pathways may still result in a normal phenotype in 
the model organism (Engle et al., 1996; Cantor 1998).  
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4. CILIA 
The implications of cilia in the vertebrate organogenesis have only recently been 
recognized. The establishment of left right asymmetry of the gastrulating embryo is 
the earliest developmental process associated with cilia. Patients with primary 
ciliary dyskinesia syndrome (PCD) have abnormalities in the organ situs which are 
caused by defects in different axonemal dynein proteins affecting the ciliary motility 
(Afzelius, 1985). Around the time of gastrulation, the embryo forms a node, which 
carries motile cilia. The cilia beat, producing a leftward flow of fluid, which is 
detected by immotile sensory cilia on the left side, "telling the left side of the 
embryo that that's the left side". Paralysis and loss of fluid flow of the embryonic 
nodal cilia in mouse mutants affecting the cilia functions have indicated the key role 
of cilia in establishing the organ situs (Brody et al., 2000; Chen et al., 1998; 
Marszlek et al., 1999, Nonaka et al., 1998). In zebrafish it has also been shown that 
the loss of the fluid flow in the Kupffer´s vesicle (KV) is associated with laterality 
defects (Kramer-Zucker et al., 2005).  
Known mouse phenotypes associated with abnormal cilial functions are CNS 
defects (hydrocephalus), bile duct hyperplasia, kidney cysts and skeletal patterning 
defects (Yoder et al., 1995; Cano et al., 2004).  Zebrafish embryos with ciliary 
dysfunction have similar developmental phenotypes as characterized in mouse 
models for cilial dysfunction. The cilia driven fluid flow is required for normal 
organogenesis in zebrafish (Kramer-Zucker et al., 2005). The mechanism by which 
ciliary dysfunction may lead to the various organ pathologies still remains unclear. 
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4.1 Virtually ubiquitous organelle in mammalian cells 
Cilia and flagella (the terms are interchangeable) are microtubule-based structures 
nucleated by modified centrioles termed basal bodies. Cilia are predominantly 
associated with epithelial cells. These small organelles are also present in 
endothelial cells, neurons, fibroblasts, chondrocytes, and many other cell types, with 
the few exceptions being avoid from cells of myeloid and lymphoid origin 
(Wheatley, 1995). The general structure of a cilium consists of a membrane-
enclosed tube surrounding a central core of microtubules (axoneme). A cross section 
of cilia axoneme reveals nine microtubule doublets (9+0) surrounding, in some cases 
a central pair of microtubules (9+2) (Takahashi, 1984). The motile 9+2 cilia are 
present on the respiratory tract, the epithelium of the oviduct, the efferent ductules 
of the testis, and the ependymal lining of the brain.  The primary cilia (9+0), found 
in many cell types, are normally non-motile, however the cilia in the embryonic 
node with 9+0 structure are motile and are capable in rotational beating (Nonaka, 
1998).  All eukaryotic cilia and flagella are surrounded by a membrane that is 
continuos with the plasma membrane, but appears to be a separate domain with a 
unique complement of membrane proteins (Handel, 1999; Brailov, 2000; Pazour, 
2002).  Cilium originates from one of the basal bodies, a modified form of centriole. 
The primary cilia are thought to be sensory organelles involved in chemo-, photo-, 
and mechanoreception (Rohlich, 1975; Burchell, 1991).   
 
 42 
Figure 7. Schematic picture of the structure of a cilium composed of the basal body 
and cilial axoneme. Modified from Zhang et al., 2004. 
 
4.2 FABB proteome 
The assembly and maintenance (ciliogenesis) of 9+2, 9+0 cilia/ flagella are 
dependent on intraflagellar transport (IFT). IFT is the bidirectional movement of 
multisubunit protein particles along axonemal microtubules, which is required for 
assembly and maintenance of eukaryotic flagella and cilia. One posited role of IFT is 
to transport flagellar precursors to the flagellar tip for assembly. The IFT was first 
described in Chlamydomononas (algae) (Kozminski, 1993) and has subsequently 
been found to be essential for the assembly of cilia in many organisms. IFT 
polypeptides are conserved in ciliated organisms from C. elegans to humans, but are 
not found in non-ciliated organisms like Saccharomyces and Arabidopsis (Cole, 
1998; Pazour, 2000). Comparative genomics study in Chlamydomonas (having 
flagella), human (having cilia) and Arabidopsis (have no cilia of flagella) has 
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resulted in the identification of the proposed human ciliary proteome, a group of 688 
gene products. These gene products compose so called flagellar (cilial) basal body 
(FABB) -proteome (Avidor-Reiss et al., 2004; Li et al., 2004). 
 
4.3 C.elegans´ X box genes 
Studies with model organisms such as C. elegans and Chlamydomonas have 
provided important information about the well conserved mechanisms in 
ciliogenesis. C. elegans has only 9+0 type of cilia and the regulation of the 
ciliogenesis in worm has also been characterized on the transcriptional level.  In C. 
elegans 60 out of the 302 neurons of the hermaphrodite are ciliated sensory neurons 
(CSN) (Ward et al., 1975) forming many structurally distinct types of sensory cilia 
The RFX-type (regulatory factor binding to the X box) transcription factor daf-19 is 
required for the sensory neuron cilium formation, and loss of daf-19 function results 
in absence of sensory cilia (Swoboda et al., 2000).  The analysis of X box sites in the 
C.elegans genome have enabled to identify genes coding peptides for the worm 
ciliary proteome that are under the control of cilia specific transcription factor daf-
19 (Efimenko et al., 2005). The high conservation of the sensory cilia in worm and 
mammals makes the nematode a significant model for the cilia functions. 
 
4.4 Cilia in the early development and cell cycle 
4.4.1 Conserved nodal cilia  
The conserved nodal cilia in different model organisms (mouse, xenopus, zebrafish 
and chicken) indicate that the activity of nodal cilia probably is a universal 
mechanism for specifying the left-right axis. The earliest known asymmetric 
expression patterns are common to all vertebrates although exhibit considerable 
variability in their time of onset among different vertebrate classes (Capdevila et al., 
2000; Wright 2001). The asymmetries are always preceded by the onset left-right 
dynein heavy chain (Lrdr) gene expression, which is a component of the ciliary 
motor and by the appearance of the cilia, indicating that nodal cilia may be 
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responsible for initiating the left-right asymmetric gene expression and for 
establishing the final body plan in all vertebrates (Essner et al., 2002).  
In human the mutations in the dynein heavy-chain gene (DNAH5) are also 
associated with immotile cilia syndrome, which is an inherited disorder that has 
mirror-image reversal of the internal organs in half of the affected individuals 
(Olbrich et al., 2002). 
 
4.4.2 Cilia in cell cycle  
The presence of a cilium is associated with establishment of polarity and 
differentiation of the cell. In tissue culture cells usually grow primary cilium as they 
approach confluence, and most ciliated cells are probably in stationary or G0 phase 
of the cell cycle (Tucker et al., 1979). In many cells the entry into the cell cycle is 
preceded by ciliary resorption whereas exit from mitosis is accompanied by ciliary 
assembly, which may reflect the use of the basal bodies/centrioles as mitotic spindle 
poles (Rieder et al., 1979; Tucker et al., 1979; Ehler et al., 1995; Wheatley, 1996).   
Research on Chlamydomonas has provided insights as to how cilia and the 
cell cycle are co-coordinately regulated. Nek family of cell cycle kinases provides an 
important general connection between cilia and regulation of the cell cycle 
progression because of the axonemal location (Quarmby et al., 2005). The many 
Neks in organisms with cilia have roles in cell cycle regulation. The only connection 
to the vertebrates comes from studies of PKD models. The causative genes of two 
mouse PKD models are Nek kinases (Nek1 and Nek8). Human Nek1 has been found 
to bind kinesin-2 and some other proteins that are required for ciliogenesis (Surpili 
et al., 2003). A kinase domain mutation of the human orthologue of Nek8 affects 
cell cycle progression, probably at G2/M checkpoint.  
There is a relationship between cilia, and cell cycle progression. Available 
data indicates that most vertebrate cells are ciliated and that the genesis and 
disassembly of the cilia is coordinated with progression through the cell cycle. 
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4.4.3 Cilia and signaling 
The kidney morphogenesis and Wnt 
The Wnt/Frizzled pathway is a major pathway (Fig. 8) implicated in the 
specification of cell and tissue polarity and operating in different developmental 
processes, including heart and neural tissue development, kidney morphogenesis, 
limb polarity and sex determination. The mouse model with disrupted inversin – 
gene (Inv/Inv) has left-right axis defects, hepatobiliary tract anomalies and severe 
renal cystic disease (Mochizuki et al, 1998; Morgan 1998).  Mutations in human the 
homolog INVS result in an infantile form of nephronophthisis (NPHP2; Otto et al., 
2003). The inversin peptide contains multiple ankyrin repeats, two D boxes and two 
calmodulin binding motifs. It associates with nephrocystin-1 (NPHP1) and this 
protein complex has been localized to the primary cilia-basal body-centrosomal 
complex (Otto et al., 2003; Morgan et al., 2002; Nurnberg et al., 2002). The kidney 
phenotype in inv/inv mice is similar to mice with dysregulated Wnt-β-catenin 
signaling proposing that Inversin is implicated in the Wnt pathway. Based on the 
studies in mouse and xenopus  it has been  shown that inversin inhibits the canonical 
Wnt signaling upstream of the β-catenin degradation complex and further the study 
in the zebrafish model showed that inversin functions as a positive regulator of the 
non-canonical Wnt signaling (Fig. 8). Further, studies on the ciliated MDCK 
(Madin-Darby canine kidney cells) showed that the passing a flow (acting as a signal 
that flips the switch from canonical to non canonical Wnt signaling) over the apical 
surface of these ciliated cells results in increased expression of inversin 
accompanied by modest reduction in  β-catenin levels (Simons et al., 2005).  This 
would suggest a model that any process that impairs this switch would result in 
unopposed canonical Wnt signaling and renal cystic disease (Simons et al., 2005; 
Germino 2005).  The essential role of unopposed canonical signaling as a central 
pathogenic failure in cystic renal disease remains still unknown and this model most 
likely will not explain all forms of polycystic kidney disease. However, the finding 
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that cilial-basal body-centrosomal complex regulates non-canonical Wnt signaling 
could explain the various genes implicated in cystic kidney disease (Germino 2005).  
 
Figure 8. Linking cilia to Wnts. Flow-based model of Wnt regulation in the kidney. 
In the model proposed by Simons et al., Wnt signaling occurs primarily through -
catenin−dependent pathways in the absence of flow. Ligand binding by the Frizzled-
LRP complex results in inactivation of the -catenin destruction complex, increased 
cytoplasmic and nuclear -catenin levels, and upregulation of effector gene 
expression (left). Stimulation of the primary cilium by flow is postulated to result in 
increased expression of inversin (Inv), which then reduces levels of cytoplasmic Dvl 
by increasing its proteasomal degradation. This process is thought to switch off the 
canonical pathway by allowing reassembly and activation of the -catenin destruction 
complex. Inversin might also enhance trafficking of Dvl to the plasma membrane, 
where it could activate noncanonical Wnt pathway components. The question marks 
indicate uncertainty as to whether the inversin-Dvl or Frizzled-LRP complexes are 
present in the primary cilia−basal body−centrosomal complex. Modified from 
Germino, 2005. 
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Hedgehog: CNS and limb bud morphology  
The specification of ventral cell types in mammalian neural tube depends on sonic 
hedgehog release from the notochord (Chiang et al., 1996; Ingham and McMahon, 
2001). Mouse studies have shown that the intraflagellar transport (IFT) proteins 
Ift172/Wimple and Polaris/Ift88 and the anterograde IFT motor protein Kinesin-2 
are required for the ciliogenesis as well as for the activation of targets on the mouse 
Hedgehog pathway by Gli transcription factors (Huangfu and Anderson, 2005). Gli3 
repressor is required for the normal anterior-posterior patterning of the limb, and the 
reduction of Gli3 can account for the polydactyly phenotype seen in partial loss of 
Polaris mouse mutants (Huangfu et al., 2003; Liu et al., 2005). It has been already 
noticed that specialized primary cilia can detect the fluid flow (mechanosensory 
cilia), and also that the somastotatin receptor 3 and serotonin 5-HT6 receptor localize 
to the primary cilia on of brain neurons (Händel et al., 1999; Brailov 2000) and thus 
suggest that the cilia have chemosensory functions. The studies with the IFT 
proteins in vertebrate model organisms propose a structural role of cilia in cells 
which is essential for responding to positive and negative Hedgehog signals 
(Huangfu and Anderson, 2005).  
 
4.5 Human ciliopathies 
The main hallmark of the known human ciliopathies is cyst formation in the kidneys, 
which occurs when the kidneys are not properly formed or the instructions for 
maintaining the proper kidney diameter are somehow missing. It has been presumed 
with the present knowledge that in all cystic kidney diseases no matter of the age of 
the clinical manifestation of the disease, the initial events of cyst formation occur 
during embryonic development (Simons and Walz, unpublished). Two of the most 
common and best characterized human disorders that can be considered as ciliopathies 
are Polycystic kidney disorders and Bardet Biedl syndrome. 
Autosomal dominant polycystic kidney disorder (ADPKD) is the most common 
human monogenic disease affecting 500-1000 in a population. ADPKD leads to end 
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stage renal disease at the age of 50-60. In ARPKD the patients suffer renal failures and 
liver fibrosis in the early childhood. Another subgroup of PKD is Nephronophthisis 
(NPHP); with prevalence of 1: 100 000 being the most frequent genetic cause of 
chronical renal failure of children.  Five different loci have been assigned so far for 
NPHP that account for approximately 50% of the cases (Otto et al., 2005).  
Several mechanisms have been proposed underlying the cyst formation in 
PKDs, but they still remain poorly understood. The PKD mouse models have shown 
the significance of the functional cilia in the pathology of the kidney cyst formation.  
 
Bardet Biedl syndrome 
Bardet Biedl syndrome (BBS, MIM 209900) is a pleiotropic condition. The 
phenotype of BBS partially overlaps with MKS. However, the BBS phenotype is 
notably milder, characterized by postaxial polydactyly, progressive retinal 
dystrophy, obesity, hypogonadism, renal dysfunction and learning difficulties. Other 
frequent symptoms are diabetes mellitus, heart disease, hepatic fibrosis, and 
neurological features. The condition is heterogeneous and already ten disease genes 
have been identified to be involved in genetics of the BBS (Nishimura et al., 2005; 
Chiang et al., personal communication and abstract: ASHG meeting 2005). 
Polydactyly, cystic kidneys, genital-, heart- and liver anomalies can be observed in 
BBS patients at the birth but not severe CNS defect (occipital encephalocele) as in 
MKS patients. The ethiology underlying BBS is dysfunction of proteins involved in 
centriole/cilia assembly and function (Ansley et al., 2003).  It has been already 
suggested in the literature that MKS and BBS might interact genetically, although 
the authors assumed that it would be unlikely that these disorders could be allelic 
(Karmous-Beinally et al., 2005).  
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AIMS OF THE PRESENT STUDY 
When this study was initiated the MKS1 locus had been assigned to chromosome 
17q and the following aims were set for this study: 
 
1. To produce physical maps for the critical MKS1 chromosomal regions in 
both human and mouse to enable and facilitate efficient candidate gene 
study (I, II). 
 
2. To identify the MKS1 disease gene in Finnish families (III). 
 
 
3. To provide initial information of the molecular pathogenesis in MKS (III). 
 
 
4. To validate the genetic heterogeneity of MKS in the Finnish families (IV).   
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SUBJECTS AND METHODS 
1. SUBJECTS 
1.1 Family material and ethical aspects 
Initially we had DNA samples from 24 Finnish MKS families (I), but 16 new 
families have been included in the study during the years 1999-2006, so at the moment 
we have samples from 40 Finnish families (III). The DNA samples are available from 
parents, MKS affected children and most of the healthy siblings. All the Finnish 
families fulfil the modern diagnostic criteria for MKS (Salonen, 1984). In addition, we 
have DNA samples from 20 non-Finnish families of European descent.  
Fibroblast cell lines have been established for most of the Finnish patients. 
The DNA samples and patient fibroblast cell lines have been obtained in 
collaboration with clinicians and genetic counsellors both in Finland and abroad.  
This study was carried out with approvals (decision numbers 28/94, 
205/E0/04, 57/E0/04) from the ethical committees of the Hospital District of 
Helsinki and Uusimaa (HUS).   
 
1.1.1 Control chromosomes and normal control tissues  
A total of 541 control DNA samples were collected from western, central and eastern 
Finland. In addition 92 CEPH grandparental DNA samples, two human variation 
panels (one with 50 Caucasian and one with 100 African American DNAs) from the 
Coriell Institute were used for carrier screening of the detected sequence alterations. 
The normal control tissues samples and fibroblast cell lines were obtained 
from fetuses aborted for social reasons.  
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2. METHODS 
2.1 Laboratory methods 
Table 1: The used laboratory methods and materials.  
Materials and methods Reference Study 
Bacterial artificial chromosomes (BAC) Shizuya et al., 1992 I 
Direct sequencing  
Maxam and Gilbert, 
1977; Sanger et al., 
1977  I, II, III, IV 
Nucleic acid extraction  Sambrook et al., 1989 I, II,  III, IV 
Electromobility shift assay (EMSA) 
Samadani and Costa, 
1996; Kyttälä masters´ 
thesis 2003 unpublished 
Fluorescence in situ hybridization (FISH) 
Pinkel et al. 1986; 
Lichter et al. 1988 I 
Haplotype analysis Ramsay et al., 1993 I, III, IV 
Linkage analysis 
Botstein et al., 1980; 
Ott, 1991 IV, unpublished  
Linkage disequilibrium (LD) analysis Hästbacka et al., 1992 I, III, IV 
Molecular cloning  Sambrook et al., 1989 unpublished 
Northern blot analysis Sambrook et al., 1989 II 
Physical mapping  Green and Olson, 1990 I, II, IV 
Polymerase chain reaction (PCR) Weber and May, 1989 I, II, III, IV 
P1 clones (PACs) Ioannou et al., 1994 I 
Reverse transcriptase PCR (RT-PCR) Ohara et al., 1989 II, III 
RNA in Situ hybridization Breitschopf et al., 1992 III 
Western blot analysis Burnette, 1981 unpublished 
Yeast artificial chromosomes (YACs) Burke et al., 1987 I 
 
2.1.1 Physical mapping  
The contiguous genomic contig (I)  
Firstly the YAC clones were identified for the MKS-MUL region (I). Clones 
positive for the previously mapped STSs and ESTs (Hudson et al., 1995; Dib et al., 
1996) between markers D17S957 and D17S1604 were provided by CEPH. 
Individual clones were cultured and total yeast DNA was extracted and stored in 
agarose beads or extracted by the alkaline lysis method. The chimerism of YAC 
clones was analyzed by the metaphase FISH technique (Bray-Ward et al., 1996), and 
clones mapping only to 17q22-q23 were used for further mapping. The presence of 
STSs and ESTs (Hudson et al., 1995; Schuler et al., 1996) in the YACs was tested 
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by PCR. The STSs and ESTs present in the YACs were used for screening of PAC 
and BAC libraries by PCR. The PAC library consisting of 321 multiwell microtiter 
plates was kindly provided by Professor Pieter J. De Jong (Roswell Park Institute, 
Buffalo, NY). The commercially available P1 library (Genome Systems, Inc., St. 
Louis, MO) and BAC library DNA pools (release III, Research Genetics, Inc., 
Huntsville, AL) were used for the P1 and BAC screenings. PCR-positive clones 
were picked and cultured in Terrific Broth media of Luria-Bertani media, 
supplemented with 25 mg/ml of kanamycin (PACs) (Ioannou et al., 1994) or 
12.5 mg/ml of chloramphenicol (BACs) (Shizuya et al., 1992). DNA was extracted 
using a Plasmid Maxiprep (tip 500) kit (Qiagen).  
 
FISH, Fluorescence in situ hybridization (I) 
The metaphase chromosome targets were achieved by culturing human peripheral 
blood lymphocytes according to standard protocols (Lemieux et al., 1992; Tenhunen 
et al. 1995). Agarose-embedded lymphocytes were used as a source of free DNA 
fibers according to the method described earlier (Heiskanen et al., 1994, 1996). All 
clones used for the FISH experiments (PACs and BACs) were labeled with biotin 
11-dUTP (Sigma) and digoxigenin 11-dUTP (Boehringer Mannheim) by nick 
translation according to standard protocols. The FISH procedure was performed as 
described earlier (Pinkel et al. 1986; Lichter et al. 1988; Aaltonen et al. 1997). 
Briefly, the hybridization mixture contained 50% formamide and 10% dextran 
sulfate in 2× SSC. Repetitive sequences were suppressed with 10-fold excess of Cot-
1 DNA (BRL, Gaithersburg, MD). After overnight incubation at 37°C the slides 
were washed at 44°C three times in 50% formamide and 2× SSC, twice in 2× SSC, 
and once in 0.5× SSC. The slides were counterstained with DAPI (Sigma).  
Digital Imaging A multicolor image analysis was used for acquisition, display and 
quantitative analysis of fiber FISH as described elsewhere (Heiskanen et al. 1996; 
Aaltonen et al. 1997). In fiber FISH, the clone sizes determined by pulse field gel 
electrophoresis (PFGE) were used as a standard for calibration in each individual 
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fiber FISH image. The distance measurements were done by applying the distance 
measurement option of the IPLab software (Signal Analytics Corp., Vienna, VA). In 
each fiber FISH image, at least one clone was used as a calibration standard to 
measure the sizes of other clones, gaps separating different clones, and overlaps 
between these clones. The known clone sizes enabled compatible and therefore 
reliable measurements to be made. If two known clone sizes were in the same 
hybridization, the results of the distance measurements were verified with each other. 
 
Isolation of Novel CA-Repeats (I, III)  
Before the genomic sequence was available novel CA-repeats were isolated from the 
PAC and BAC clones (I, Klockars et al., 1996; Ranta et al., 1997). Shortly, PAC 
DNA was digested with Sau3A1 and ligated to pGEM7, transformed into DH5  
cells and plated onto selective agar plates. BAC DNA was digested with RsaI and 
ligated to SmaI-cut pUC18 vector (Pharmacia, Biotech), transformed into Epicurian 
Coli SURE competent cells (Stratagene), and plated onto selective agar plates. The 
colonies were transferred onto nylon filters (Hybond-N, Amersham or Magna Chart, 
MSI) and hybridized with a radioactively labeled (GT)16 oligonucleotide at 65°C 
overnight. After autoradiography, positive colonies were selected, and DNA was 
isolated using a Plasmid Miniprep (tip 20) kit (Qiagen) or Wizard Plus Miniprep kit 
(Promega). The inserts were sequenced with SP6 and T7 vector primers. 
Oligonucleotide primers flanking the CA-repeats were selected with Primer3 
software (Whitehead Institute). Nowadays the repeats are identified directly from the 
genomic sequence and the putative polymorphism is tested in chromosomes 
representing the population (III). 
 
2.1.2 Candidate gene studies in the patients 
The positional candidate genes for MKS1 were selected by monitoring the shortest 
region of shared homozygosity in the Finnish MKS chromosomes (I, III). We chose 
three Finnish patients with the common Finnish disease haplotype in the marker interval 
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(17q: D17S1290-132-CA (I), and later D17S2263-D17S1290 (III) for the candidate gene 
sequencing. In addition, we extracted RNA for northern blot and RT-PCR analyses from 
fibroblast cell lines and from frozen tissue biopsies (in liquid Nitrogen) from patients 
with the common Finnish MKS haplotype and normal controls.  
 
Candidate gene sequencing 
The coding regions and intron-exon boundaries of the candidate genes were 
sequenced from genomic DNA and RT-PCR products. PCR primers were designed 
with the Primer3 program (Whitehead Institute).  
PCR products were enzymatically purified (schrimp alkaline phosphatase and 
EXOI, Amersham Pharmasia) and bidirectionally sequenced with BigDye 
Terminator chemistry on 377/3730 DNA Analyzer (Applied Biosystems). We 
analyzed the sequences with Sequencher software (Gene Codes; v. 4.0.5).    
 
Electromobility shift assay, EMSA (Kyttälä, 2003) 
The nuclear extract was extracted from the human embryonic kidney cell line 
HEK293T by following the protocol by Andrews and Faller (1991). The EMSA 
assay conditions reported by Samadani and Costa (1996) were slightly modified.  
The DNA-protein hybridization contained 2ng labeled DNA probe (PCR product/ 
61-mer oligo), 20 mM HEPES (pH 7.9), 4% Ficoll, 2mM MgCl2, 40 mM KCl, 0.1 
mM EGTA, 0.5 mM DDT (dithiotreiol), 4 ng sonicated salmon sperm and 40 ng of 
the nuclear extract from the HEK293T cells.  
Two different types of DNA probes were utilized: ds 61-mer oligos and PCR 
products. Both type of DNA probes were tested for the wild type (normal control) 
sequence and for the patient sequence (homozygous for the SEPT4 gene G-allele; 
mRNA GI_17986248, bp 594).   
The used ds 61-mer oligos for patient and wild type alleles were (only the forward 
strand sequence shown): G GAG TGT GTG GTG GTG GTG GTG GTG GTG GTG 
GTG GTG GTG TGT T/G TG TGT GTG TGT GTA TCT. The underlined T/G 
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bases show the site of observed sequence alteration in the patients (T→G). The 
results, which were obtained with the ds oligos, were verified with PCR amplified 
DNA probes (146 bp in size) from patient and control DNA templates. The PAGE 
and blotting were performed in standard non-denaturating conditions. The ds 61-mer 
oligos and PCR amplified DNA probes were both detected in ECL (biotinylated 
DNA probe) (Amersham Biosciences) and in autoradiography with 32P labeling 
(Redivue γ-32P-ATP, Amersham Biosciences).   
 
Northern blot (II, unpublished) 
The transcripts were analyzed on blots generated from 3 μg of mRNA extracted 
from fetal tissue (MKS and normal control) by using the Direct mRNA midi kit 
(Qiagen) following the manufacturer’s protocol. Probes: 400 to 500 bp DNA 
fragments were generated by RT-PCR amplification, and 32P labeled with a random 
priming kit (Invitrogen). Blots were hybridized with the Express-Hyb solution 
(Clontech), as recommended by the manufacturer. 
 
2.1.3 Genotyping  
Polymorphic markers were amplified by PCR and the fragments were analyzed on 377 
(I) or 3730 (III, IV) DNA Analyzers (Applied Biosystems). The allele sizes were 
determined using the size standard provided by the manufacturer with the standard 
software package (GeneMapper v.3.7). 
  
10K SNP array (IV) 
The genome wide SNP analysis was undertaken by using the GeneChip® Human 
Mapping 10K Array Xba 131 and assay kit (Affymetrix, Santa Clara, CA). The 10K 
array contains nearly 11 500 SNPs and the median intermarker distance is 
approximately 200 kb. An average heterozygosity of 0.37 for these SNPs is reported 
by the manufacturer. The assay was performed according to the Affymetrix 
GeneChip® Mapping Assay Manual. SNP-genotypes were obtained by following 
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the protocol for the GeneChip® mapping 10K Xba Array. All analyzed DNA-
samples achieved over 95% call rate.   
 
Genome-wide scan with microsatellite-markers (IV) 
The genome-wide scan with 380 multiallelic markers (Applied Biosystems) was 
performed by The Finnish Genome Center (FGC) (http://www.genome.helsinki.fi/).  
 
2.2 Biocomputing programs and statistical analyses 
Table 2: Biocomputing programs and databases utilized in computational analysis.  
Program/ 
Database 
Brief description URL/ Reference Study  
Blast  Sequence alignments and 
comparisons. 
http://www.ncbi.nlm.nih.gov/BLA
ST/ 
I, II, III 
Boxshade Organizes the results from 
multiple sequence alignments 
to a visually  
http://www.ch.embnet.org/softw
are/BOX_form.html  
III 
ClustalW Multiple sequence alignment 
tool. 
http://searchlauncher.bcm.tmc.e
du/multi-align/multi-align.html 
III 
GENEHUNTER Multpoint calculations. Kruglyak et al., 1996 IV, 
unpublished  
Genotator Gene prediction: an annotation 
workbench that runs various 
sequence analysis programs  
Harris, 1997 II 
Genscan Gene prediction: Predicts exon-
intron structures of genes in 
genomic sequences  
Burge and Karlin, 1997 II, III 
Linkage package  Basic linkage calculations. Lathrop et al., 1985 IV, 
unpublished  
MAPMAKER/ 
HOMOZ 
Rapid multipoint analysis in 
nuclear pedigrees. 
Kruglyak et al., 1995 IV 
MatInspector Transcription factor binding site 
prediction program. 
http://www.genomatix.de/ 
online_help/help_matinspector/
matinspector_help.html 
unpublished 
NCBI main page Genome data from different 
species and tools to analyze 
them. Contains links to a 
variety of other genome and 
related resourses. 
http://www.ncbi.nlm.nih.gov/ I, II, III, IV 
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Pfam Predicts domains based on the 
peptide sequence. 
http://www.sanger.ac.uk/ 
Software/Pfam/ 
III 
Primer3 Primer design. http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi; 
Rozen and Skaletsky, 2000 
I,II, III, IV 
Prosite Proteomic tools. http://au.expasy.org/prosite/; 
Hofmann et al., 1999 
III 
PSORT Predicts cellular localization for 
peptide sequence. 
http://www.psort.org/ unpublished 
UCSC genome 
bioinformatics 
Genome data from different 
species and tools to analyze 
them. Contains links to a 
variety of other genome and 
related resourses. 
http://hgdownload.cse.ucsc. 
edu/downloads.html 
II, III, IV 
 
2.2.1 Statistical analysis  
Linkage  
The two point LOD-scores were calculated using the linkage package program 
MLINK (Lathrop et al., 1985). Autosomal recessive inheritance with full penetrance 
and estimated disease allele frequency 0.001 were used in the calculations.  
 
LD analysis   
The significance of LD between the disease and marker loci was analyzed using the 
DISLAMB program (Terwilliger, 1995). This program applies a likelihood-based 
test for linkage disequilibrium and has only one degree of freedom, irrespective of 
the number of alleles at any given marker. The calculations are based on the 
parameter , which expresses the proportion of the increase of a certain allele in the 
disease chromosomes, relative to its population frequency. Confidence intervals for 
 were calculated for 1-lod units. The most likely haplotypes were constructed 
manually, assuming a minimum number of recombinations in each family. 
 
Multipoint analysis of the 10K SNP array with MAPMAKER/HOMOZ program (IV) 
We analyzed the genotypes produced with the 10K SNP (Affymetrix) array with the 
MAPMAKER/HOMOZ program (Kruglyak et al., 1995) for finding the regions of 
the shared homozygosity by the affected siblings. This program has been developed 
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for fast multipoint linkage analysis in small nuclear families. The fundamental 
assumption was that the parents have common ancestors (IV). The SNP markers on 
the 10K array were localized on the genetic map by using the data provided by 
Affymetrix. The missing genetic map information was estimated for some of the 
markers by utilizing their known physical position, and using linear interpolation 
with the adjacent SNP markers for which both physical and genetic map information 
was known. The markers were arranged into sets of 70 adjacent markers with 20 
markers overlap between marker sets on a given chromosome. The genetic map 
positions of SNP-markers were converted to the Haldane units. The allelic 
frequencies were used as provided by Affymetrix in the Caucasian population, 
derived from the larger sample size. Five out of 11 229 SNP markers were void of 
allelic frequency information (SNP_A_1511539, on Chr5; SNP_A_1513409, on 
Chr11; SNP_A_1512847, on Chr12; SNP_A_1508640, on Chr15; and 
SNP_A_1511759, on Chr16) and were left out of the analysis. The SNP multipoint 
linkage analysis was performed by utilizing MAPMAKER/HOMOZ (v. 0.9) 
program with increments of 1 cM and 20 cM beyond the ends of the chromosomes.  
 
2.3 RNA in situ hybridization of Mks1 (I)  
The RNA In situ hybridization was performed to sections of mouse embryos 
(C57BL/National Public Health Institute, Helsinki, Finland) at embryonic day 15.5 
(E15.5). The embryos were fixed by overnight immersion in 4% PFA in 0.1 M PB, 
pH 7.4. Samples were embedded in paraffin and cut into 5 µm thick sagittal sections. 
Mounting was performed onto SuperFrost/Plus microscope slides (Merck, 
Germany). The study is approved by the animal care and use committee of the 
National Public Health Institute, Helsinki, Finland. The work has been carried out 
following the good practice in handling of laboratory animals. The probe was 
produced by amplifying cDNA derived from a mouse fibroblast cell line with the 
Mks1 specific primers: Insitu-F: AAGGGTTCAGCCAGCAGAGT; Insitu-R: 
TGGTTGCCAAACTCCCTTT. The 500 bp probe fragment was cloned into the 
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pGEM-T Easy Vector (Promega) and the anti-sense and sense probes with the 
digoxigenin label were created with a DIG RNA labeling kit (Roche), according to 
the manufacturer's protocol. The probes were diluted in 1:400 in a hybridization 
buffer containing 2x SSC, 10% dextran sulfate, 0.01% sheared salmon sperm DNA, 
0.02% SDS and 50% formamide. A method described by Breitschopf and coworkers 
(1992) was used for the hybridization with slight modifications. Photographing and 
analysis of the samples were performed using a Leica microscope equipped with 
DC300F camera and IM1000 software and a Zeiss Axioplan 2 imaging microscope 
(Zeiss). The final figures were prepared by using CorelDraw v.12 and Paint Shop 
Pro v.7.04 softwares.   
 
2.4 Transient expression of MKS1 (unpublished) 
Plasmid construct  
The protein coding region of the MKS1 cDNA was amplified by RT-PCR with 
primers coding-F: ATGGCGGAGACCGTCTGGA and coding-R: 
CTAGGAGACCAGGGTTCCA. The RT-PCR product was cloned into pCR-BluntII-
TOPO vector by using Zero blunt TOPO-PCR Cloning kit (Invitrogen) following 
manufacturers´ guidelines. The MKS1 insert was restricted from pCR-BluntII-TOPO 
vector with NsiI (NEB) and ligated with T4-ligase (NEB) to pEGFp-C1 vector 
restricted with PstI (NEB). The N-terminally GFP-tagged MKS1 construct was 
verified by sequencing and in western blot with GFP-antibody, which produced a band 
agreeing with the size of GFP-MKS1 fusion protein. The cell lysate for the western 
blot was made of HEK293 cells transiently transfected with Fugene 6 (Roche). 
 
Cell culture  
HEK293 and fibroblast cell lines were maintained in DMEM supplemented with 
10% fetal bovine serum (FBS), 2 mM glutamine, 100 IU/ml penicillin and 100 
μg/ml streptomycin at 37ºC degrees in 5% CO2. 
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Immunofluorescence  
Cells were grown on cover slips washed in phosphate buffered saline (PBS) and 
fixed with 4% paraformaldehyde (PFA). The cover slips were rinsed with PBS and 
permeabilized with 0.1% Triton x-100/0.5% bovine serum albumin (BSA) in PBS 
for 15 min in RT. Washed twice with PBS and blocked with 0.5% BSA in PBS for 
30 min in RT. The cover slips were incubated for 1 h in RT with monoclonal anti-
polyglutamylated tubulin mouse immunoglobulin (T9822, Sigma-Aldrich), which 
was diluted 1:16 000 into the blocking solution. Same procedure was repeated with 
the TRITC conjugated secondary antibody. Cover slips were finally washed twice 
with PBS and with dH2O prior mounting. 
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RESULTS AND DISCUSSION  
1. PHYSICAL MAP OF THE MKS1 LOCUS ON 17q23  
The original linkage study by Paavola and colleagues (1995) assigned the first MKS 
locus (MKS1) to a 13 cM region on chromosome 17q in Finnish families.  At that 
time, the public genetic maps for the region were inadequate for LD based mapping 
and direct candidate gene studies. Soon after, the MKS1 region was restricted to 5 
cM between markers D17S1606 and D17S807 (Paavola et al., unpublished), but the 
exact physical size and gene content of the chromosomal region was missing. When 
the gene defect causing Mulibrey Nanism (MUL, MIM 253250) was assigned to the 
same chromosomal region on 17q (Avela et al., 1997), a close collaboration was 
initiated for physical mapping of the overlapping MKS-MUL loci together with the 
MUL research group.   
 In the beginning of physical mapping project a contig of genomic YAC clones 
was available for the human genome covering approximately 75% of the genome 
(Chumakov et al., 1995). This provided the basis of the MKS-MUL physical map. 
The YAC clones were utilized for STS-content mapping to confirm the order of the 
clones and the available STSs. We screened PAC and BAC libraries (Shizuya et al., 
1992; Ioannou et al., 1994) with the available STSs and expressed sequence tags 
(ESTs) to construct a multiple coverage of genomic PAC and BAC clones  and to 
generate additional microsatellite markers, which enabled the LD and haplotype 
mapping in the critical disease gene regions.  
 
1.1 Initially restricted critical chromosomal region 
Six novel dinucleotide repeat markers were isolated from three PAC (95i19, 52i20, 
and 58p18) and two BAC (272g3 and 132i10) clones on the 17q23 region. These 
were the markers: 95-CA, 272a-CA, 272b-CA, 132-CA, 58-CA and 52-CA) (Fig. 1).   
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Figure 1. The physical map of the 17q MKS-MUL critical region. The horizontal bars 
stand for the multiple coverage YAC (with black line on top), PAC (black) and BAC 
(grey) clones. At the time only two sequenced genomic clones were available in the 
Genbank (NCBI) for the region: hRPK.506h21 and hRPC.1171i10. The dashed arrow 
lines indicate the genes which were later found to be defective in MUL (Avela et al. 
2000) and MKS (III).  
 
The original assumption was that all the 24 Finnish families available for us at the 
time would have mutations in the same gene on chromosome 17q. Due to this all the 
disease chromosomes were included in the LD and haplotype analyses. This defined 
a minimum 1 cM genetic region for the MKS locus between the markers D17S1290 
and 132-CA (Fig. 2, on page 64). Five patients were thought to be compound 
heterozygous for the common MKS haplotype and another haplotype, and in two 
patients, both chromosomes differed from the common MKS haplotype. In seven of 
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the patients, four different putatively rare MKS haplotypes were observed and those 
were interpreted to represent probable "minor" MKS mutations.  
 The insert sizes of the PAC and BAC clones constituting the minimum tiling 
path of the contig were determined by using restriction digestion followed by 
pulsed-field gel electrophoresis. Fiber FISH analyses were used to verify and 
confirm these size estimations. In fiber FISH, one or two bacterial clones, whose 
sizes were determined by PFGE, were used as a standard for calibration in each 
hybridization image to estimate the sizes of other clones. According to the PFGE 
data and fiber FISH, the size of the contig from D17S1290 to 52-CA, that is also the 
critical region for MUL, was estimated to be ~1.4 Mb. Furthermore, the total 
physical length of the critical region for MKS was determined to be ~800 kb 
between the markers D17S1290 and 132-CA (Fig. 1). 
 The detailed physical map enabled us to precisely localize a total of 20 ESTs 
of both known and unknown homology, which were previously only roughly 
assigned either by radiation hybrid mapping or by STS-content mapping to the YAC 
clones in the region (Fig. 1) These ESTs were derived from the gene map of the 
human genome (Schuler et al.,  1996).  
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1.2 Discussion of the impacts of the physical map 
Before the genomic sequence and transcript maps were available physical mapping 
was a necessity prior to positional candidate gene analysis. It also enabled the LD 
and haplotype analysis with novel dense markers in disease chromosomes. The 
physical map made it possible to exclude functionally significant candidate genes 
based on their physical position 
 The assigned gene loci for MKS and MUL overlapped but it was not clear 
whether these two disorders were allelic or not. The MUL gene was found in the distal 
part of the MKS region by Avela and colleagues in 2000 (Fig. 1). The gene mutated in 
MUL did not contain any pathogenic sequence alterations in direct sequencing of the 
genomic- and RT-PCR products in the MKS patients. The northern analysis of the 
MUL gene in  patients´ tissue samples did not detect any changes in the expression 
levels nor in the transcript sizes when compared to a normal controls (Kyttälä et al., 
unpublished).  
 The size of the MKS1 critical chromosomal region (D171290-132-CA) was 
estimated to be 800 kb by pulsed field gel electrophoresis and fiber FISH analysis. 
This agrees very well with the exact size of  782 254 bp (USCS, genome browser, 
May 2004). 
 
2. HUMAN AND MOUSE COMPARATIVE MAPS OF MKS REGIONS 
Comparative genomics in human and mouse was utilized to facilitate the positional 
cloning of the MKS gene on the human chromosome 17q. The critical MKS region 
was restricted in the LD and haplotype analyses between the marker interval 
D171290-132-CA, which is 800 kb in size. We identified the mouse syntenic 
regions for the three known human MKS loci and the gene content and order in 
them. Initially the available public genomic sequences and transcript maps in both 
species were incomplete alone. The comparative genomics provided an alternative 
tool to extract more information from the regional candidate genes. Reciprocal 
comparisons of the known transcripts, ESTs and genomic sequences in human and 
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mouse enabled us to predict the correct gene structures and the regional gene order 
in both species. This was done by utilizing the blast tools (UCSC, NCBI), but for the 
human and mouse MKS1 loci the results were also verified experimentally by PCR 
and RT-PCR.   
Ideally we could have identified a novel mouse gene in one of the three 
syntenic MKS loci, which function and gene expression pattern would have agreed 
with the MKS phenotype. This type of mouse ortholog would have represented an 
excellent functional and positional candidate gene for MKS. The identification of a 
mouse ortholog for the human MKS gene at the MKS2 or MKS3 loci could have 
provided essential functional information for the identification of the MKS1 gene on 
human chromosome 17q. In the most optimal circumstances we could have 
identified a mouse phenotype mimicking the patient phenotype caused by a mutation 
in a gene at the mouse syntenic MKS1 locus. In addition, the identification of the 
conserved non coding sequences could have indicated important regulatory elements 
in the human MKS1 region.  The identification of the conserved regulatory regions 
was relevant, since no coding region mutations had not been detected in the regional 
candidates in the patients by the time Original publication II was published (2004).  
At that time, the finished genomic sequence was already available and the transcript 
map for the chromosome 17q23 locus was complete.  
 
2.1 Syntenic mouse MKS1 locus 
The comparative mapping project was conducted in a collaboration with a research 
group screening recessive mouse phenotypes which were produced with the point 
mutagen ENU (N-ethyl-N-nitrosourea) and a balancer chromosome, inversion on mouse 
chromosome 11, which  covered the mouse syntenic MKS1 region (Kile et al. 2003).  
The mouse chromosome 11C is syntenic to human chromosome 17q23 (Fig. 3).  
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Figure 3: The human and mouse MKS1 critical regions.  On the left is the original 
MKS1 linkage region on human Chr17, spanning 17q12 – 17q23.3.  On the right is 
the corresponding mouse genomic region, from 46 –63 cM on mouse Chr11. Note, 
the MKS1 critical region is shown as a box next to the human and mouse 
chromosomes.  Original publication II. 
 
We observed only small differences in human and mouse MKS loci on the 
gene coding regions: The order of sept4 (PNUTL)-gene (NM_004574) and flj12338 
(AK022400) transcript differed between species and the homolog for the putative 
human transcript FLJ20264 (AK000271) was missing completely from the mouse 
MKS syntenic region on chromosome 11C (Fig. 4). The mouse syntenic MKS1 
locus was slightly smaller in size (500 kb) compared to the 800 kb MKS1 locus on 
human chromosome 17q23.   
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Figure 4. The human MKS1 critical region extends from D17S1290 – 132CA. BAC 
clones are shown as grey boxes. Genes in the MKS1 interval are shown in the 
middle. The transcript direction is shown as black arrows. The corresponding mouse 
genomic region is shown below the human. Mouse BAC clones are shown as gray 
boxes, and mouse transcript direction is shown as black arrows. The identified 
MKS1 gene is the second transcript on the left (FLJ20345). Original publication II. 
 
2.2 Discussion of the comparative mapping  
The comparative mapping demonstrated high conservation of the syntenic MKS1 
regions in human and mouse, both in gene order and content. This supports the idea 
of mouse being a good animal model for human MKS as a mammal and allowing 
targeted mutagenesis in its genome.  
Unfortunately the ENU-mutagenesis project conducted by our collaborators 
did not produce phenotypes similar to human MKS, which could have potentially 
represented a mutation in the mouse Mks1 gene. This could have provided an 
 69 
alternative tool for the MKS gene identification in human. The comparative 
genomics of the two other MKS loci (MKS2 and MKS3) in human (11q and 8q) and 
mouse (chr7 and chr15) did not either provide any resolving information of the 
MKS gene on human chromosome 17q.  
The MKS3 locus was initially mapped too far to the distal part of 
chromosome 8q24 (Morgan et al., 2002). This was recently recognized when the 
MKS3 gene was identified to be mutated in MKS on 8q22 (Smith et al., 2006).  The 
future studies will show if the MKS2 locus have been assigned correctly to 
chromosome 11q13 (Roume et al., 1998). The original linkage is often pointing to a 
vast chromosomal region and a careful analysis of the disease chromosomes with 
densely distributed markers is required in most cases to establish the minimum 
chromosomal region for the disease gene. In the case of MKS the locus 
heterogeneity can cause major disturbances in this type of studies.  
 
3. EXCLUSION OF THE CANDIDATE GENES  
3.1 Analysis of a rare sequence variant in the disease chromosomes  
The scrutiny of the 800 kb critical MKS region, which was restricted between the 
markers D17S1290-132-CA on chromosome 17q23.2, demonstrated that it contains 
total of 13 transcripts (Fig. 4; on page 68: MPO-TRIM37).  The direct sequencing of 
these transcripts in the Finnish MKS patients revealed only non pathogenic 
polymorphisms and one rare variant in the mRNA variant 4 (NM_080417) of the 
SEPT4 (PNUTL)-gene. The variant was bp 594 T→G (NM_080417) on non coding 
region of the 5´ UTR. This allele was observed to be in complete LD in the 23 
unrelated patients (p= 0.00) with the common MKS haplotype on chromosome 
17q23. We screened the carrier frequency of this rare variant in over 1000 Finnish 
control chromosomes and it correlated well with the estimated carrier frequency of 
Finnish founder  mutation (common disease associated haplotype) in the families. 
We were not able to detect any alterations in the patients’ transcript of SEPT4 gene 
in the RT-PCR and northern analysis when compared to normal controls.   
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MatInspector program predicted for the genomic sequence on this particular 
region a transcription factor binding site for HFH-transcription factor, which was 
missing in the patients´ sequence with the T→G transition. However, we were not 
able to confirm this in electro mobility shift assay (EMSA). In the EMSA analysis 
we utilized nuclear extract from human embryonic kidney cell line (HEK 293), but 
no specific shift was observed in this analysis. This indicates that the prediction  by 
the MatInspector program might be invalid (Kyttälä, 2003, Masters´ thesis).  
Finally, all the 13 transcripts on chromosome 17q23.2:  bp 53,686,396- 
54,468,630 (UCSC May 2004 assembly) were excluded in the candidate gene 
analysis based on direct sequencing and RT-PCR sequencing and/or northern 
analysis in patient and control samples (Kyttälä et al., unpublished; Table 1.).  
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Table 1. The excluded regional transcripts on the marker interval D17S1290- 132-
CA (Kyttälä et al., unpublished). The dark colour indicates the methods which have 
been used for the exclusion of the regional candidate genes. The Transcript 
FLJ20264 (Fig. 4) is not included to the table since it exists no longer in Genbank.  
 
         Transcript     Sequencing of the patient DNA   Northern 
Name; Genbank acc#         Genomic          cDNA   analysis 
LPO, NM_006151  
MPO, NM_000250  
PRAX-1, NM_004758    
SUPT4H1, NM_003168  
FJL20315, NM_017763  
HSM802074, BC033020  
MTMR4, NM_004687  
SEPT4, NM_004574  
FJL12338, BC022189  
TEX14, NM_198393  
RAD51c, NM_002876    
PPM1E, NM_014906    
TRIM37, NM_001005207     
 
3.2 Discussion and the exclusion of the entire initial candidate region 
(D17S1290-132-CA) 
The analysis of the regional candidate genes did not detect any mutations in the 
Finnish MKS patients. The rare variant in the SEPT4 gene was excluded as the 
disease causing mutation. This was based on the observation of normal transcripts in 
the patients and the functional analysis of the variant. The exclusion was confirmed 
after additional MKS disease chromosomes with more informative meiotic 
recombinations were available for us, since the SEPT4 gene is located outside of the 
refined MKS locus (see 4.1 Final restriction of MKS1 locus). 
However, the rare variant (T/G) of the SEPT4 gene provided a very specific 
marker for MKS chromosomes since the allele G was originally detected in 
complete LD in 23 Finnish families with the common MKS haplotype. The genetic 
heterogeneity had been established in MKS and we began to use this rare variant as 
the criterion for Finnish families to have linkage to chromosome 17q23 region. By 
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analysing only the disease chromosomes of the patients who were either 
homozygous or heterozygous for the G-allele, we observed that there was only one 
disease chromosome, which restricted the critical region proximally to the marker 
D17S1290 (Fig. 5a: The haplotype on the second row from top). The genotypes with 
the novel markers detected significant LD on proximal region of the marker 
D17S1290 (Fig. 5a). The analyses of the disease haplotypes in the 26 Finnish MKS 
families excluded eventually completely the region that was initially restricted 
between the markers D17S1290-132-CA (Fig. 5). 
 
4. IDENTIFICATION OF THE MKS1 GENE 
4.1 Final restriction of MKS1 locus  
The new families which had participated in the study after construction of the 
original physical map (Fig. 1) demonstrated the deficient restriction of the critical 
chromosomal region on the proximal site of marker D17S1290. There were no 
genotype data available from the Finnish disease chromosomes on this region except 
the original linkage marker D17S1606 (Paavola et al., 1995), which locates 
proximally 1 cM apart from the D17S1290. Unluckily the allelic mutation in the 
disease chromosome with D17S1290 (Fig. 5a: the haplotype on the 2nd row) had an 
impact on the initial disease locus restriction. The locus heterogeneity in Finnish 
MKS families interfered the haplotype mapping of the MKS1 locus.   
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Since there were no markers available in the database (UCSC, human genome 
browser, May 2004) on the near proximal region to the marker D17S1290, we 
constructed four new polymorphic markers (D17S2261-D17S2264) in this particular 
region in the close vicinity of D17S1290 by utilizing polymorphic short tandem 
repeats in the genomic sequence.  The genotypes with the novel markers in Finnish 
disease chromosomes greatly facilitated the final restriction of the chromosome 17q 
MKS locus to 99 kb (Fig. 5b).  This newly assigned MKS critical chromosomal 
region was restricted between the markers D17S2262-D17S1290 and it contains 
only five transcripts (UCSC May 2004 assembly).  
 
 Figure 5.   
 a) The markers and marker alleles in the disease chromosomes of 26 Finnish 
unrelated MKS families with confirmed linkage to chr17q23. MKS1Δ marks the 29 
bp intronic deletion (Δ) of MKS1 gene. This allele is in complete LD in the disease 
chromosomes (p= 0.00). The alleles marked with bold font are the same size as 
alleles which are seen in the full length disease haplotype (the 1st row). The alleles 
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marked with Italics represent alleles with probable allele mutation in the ancient 
disease chromosome (haplotypes on the 2nd and 3rd row). Grey color shows 
recombination haplotypes.  
b) The transcript map of the restricted 99 kb MKS1 region on chr17q23. We 
sequenced the coding regions and exon-intron boundaries of the transcripts in the 
patients. The only pathogenic sequence alteration was found in the MKS1 gene.  
c) The genomic structure of the MKS1 gene. The longest open reading frame is 
coded by the exons 1-18, which is the region between bp: 76-1755, of the 2267 bp 
long cDNA (DQ185029). The exon 16 is missing from the MKS1 transcript in the 
Finnish patients homozygous for the 29 bp intronic deletion. This is the founder 
mutation in Finland (FINmajor mutation).  The black arrows on the transcripts are 
pointing the 5´-3´ orientation. Original publication III. 
 
4.2 MKS1 mutations in patients  
The sequencing of the four of the regional (D17S2262-D17S1290) genes revealed 
only non pathogenic polymorphism in direct sequencing of three Finnish patients 
and one German patient with strong evidence of linkage to MKS1 locus. The 
sequencing of the novel gene MKS1 (FLJ20345) detected a 29 bp deletion in intron 
15 only four bp apart from the splice acceptor site (Fig. 5c).  We sequenced the 
MKS1 gene in 20 non-Finnish MKS families available to us and identified disease 
causing mutations in four of them. In three of the non-Finnish families the affected 
individuals were homozygous for the Finnish founder mutation. One MKS case of 
German ancestry was found to be a compound heterozygote for two different 
mutations in MKS1. Both mutations are located at the very beginning of the 
transcript: a five bp insertion in exon 1 (50insCCGGG) causing a frame shift and a 
T→C substitution at the splice donor site in intron 1 (IVS1+2T→C) (Table 2).  
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Table 2. The identified patient mutations in MKS1 gene. Grey highlighting marks 
the FINmajor mutation. All the patients in the Finnish families were homozygous for 
this mutation. The FINmajor mutation was found in homozygous form also in four 
non-Finnish families of European descent.  
 
Mutation  Consequence in the gene product  exon  intron 
IVS15-7_35del P470fsX562 -  15 
50insCCGGG P17fsX163 1  - 
IVS1+2T→C splicing -  1 
 
 All the patients in the 26 Finnish families were homozygous for the FINmajor 
mutation and we could not identify other mutations in the sequence analysis of the 14 
kb MKS1 gene in the remaining 14 (30%) Finnish MKS families. However, in these 
families the common disease haplotype is not observed and the definitive evidence for 
the linkage to 17q23 is missing in these families with one affected child. This would 
suggest that mutations in the other two known or in some still uncharacterized MKS 
loci would explain the molecular background in these families.  
 
The consequence of the FINmajor mutation in the patient transcript  
To investigate the effect of the intronic deletion on the mRNA level, we analyzed 
the RT-PCR products from MKS (n= 3) and control fibroblasts (n= 6). A size 
difference was observed in agarose gel electrophoresis and sequence analysis of the 
RT-PCR products demonstrated that the patients´ transcript misses 83 bp 
encompassing exon 16 (Figs 6a and b).  To confirm the presence of this exon in 
various control tissues, we performed PCR analysis of the cDNAs from the fetal 
multiple tissue panel (BD Biosciences). All the tested tissue samples produced one 
major product containing exon 16, which was missing from the patients´ transcript.  
The FINmajor mutation is a 29 bp intronic deletion which locates only four bp apart 
from the splice acceptor site, and most likely grounds to a lacking splice branching 
site in intron 15, which leads to incorrect spliced patient transcript missing 
completely exon 16.   
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Figure 6. 
a) RT-PCR products which are made with primers flanking exon 16 of the MKS1 
gene. On lanes 1-8 are the cDNAs from the embryonic MTC panel (Clontech): 1. 
brain, 2. lung, 3. liver, 4. kidney, 5. heart, 6. spleen, 7. thymus and 8. skeletal 
muscle. Lane 9: control embryonic skin fibroblast cDNA. Lanes 10-12 skin 
fibroblast cDNAs of patients homozygous for the FINmajor mutation. The size 
difference of healthy control transcript and the FINmajor homozygous patient is 83 
bp, which is the size of exon 16. Lane 13. water. 
b) RT-PCR from skin fibroblast RNA across the 18 exons of MKS1 including the 
first methionine and STOP codons. Lanes: 1. Control (WT/WT), 2. FINmajor 
homozygous patient 3. Water. 
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4.3 FINmajor -mutation: Age and carrier frequency in Finland 
The carrier frequency of the identified 29 bp intronic deletion was found to be 1% 
among 1082 Finnish control chromosomes, the prevalence well correlating with the 
estimated 1.5% carrier frequency of the Finnish MKS founder mutation (FINmajor). 
Based on the available MKS samples and Hardy Weinberg (HW) calculations, we 
would estimate that approximately 70% of the Finnish cases are homozygous for the 
founder mutation. MKS is enriched in the Finnish population, the prevalence being 
one in 9000 newborn (Salonen and Norio, 1984), but it does not show 
geographically regional clustering, unlike most of the diseases belonging to FDH. 
Not even when dividing the families into two separate groups. Group1: Families 
with FINmajor mutation (70%) and group2: Families with mutation(s) in other gene(s) 
(30%). The grandparental birthplaces in these both groups reflect geographically the 
population density rather than showing regional clustering. Also the interval of 
significant linkage disequilibrium (LD) in Finnish MKS alleles is exceptionally 
short spanning only some 1 cM region on 17q, the average LD interval in 16 other 
diseases belonging to the FDH being 6.3 cM (Peltonen et al., 1999). These findings 
imply that the MKS1-FINmajor mutation is older than the most FINmajor mutations of 
FDH. Since our mutation detection in MKS1 gene identified non-Finnish patients of 
European descent who were homozygous for the FINmajor mutation, it is very likely 
that the MKS1-FINmajor mutation has been introduced early to the European gene 
pool and the mutation has entered to the area of Finland with the first inhabitants 
immigrating from south. 
 
4.4 Discussion of the mutations in the MKS1 gene 
The old age of the FINmajor-mutation is supported by the small chromosomal region 
of significant LD the disease chromosomes and the geographical distribution of the 
disease throughout the country, opposite to most of the diseases in FDH. Also the 
identification of this mutation in homozygous form in patients in non-Finnish 
families of European descent suggests that the mutation has been introduced early to 
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the European gene pool. The homozygous FINmajor mutations result in the same 
outcome than the compound heterozygous mutations at the very beginning of the 
gene. A frame shift in exon one and a splice donor site mutation in intron one would 
support the idea that a FINmajor homozygous patient most likely represents a null 
mutation of MKS1 lacking completely the gene product. In theory a patient 
homozygous for  FINmajor –mutation would have a peptide with frame shift error at 
position 470 aa (P470fsX562), the size of the wild type peptide being 559 aa. 
However, we could not detect expression level alterations in the MKS1 transcript in 
expression array analysis (Affymetrix Genechip® HG U133 Plus 2.0 Array) in the 
total RNA samples from  patients´ skin fibroblast cell lines when compared  to 
normal controls (Kyttälä et al., unpublished). However, it requires further 
investigitaion to confirm that this applies to all the tissue types. 
  
5. INITIAL CHRACTERIZATION OF THE NOVEL HUMAN GENE, MKS1 
The MKS1 represented a novel human gene with unidentified biological function. It 
contains an open reading frame (DQ185029: bp 76-1755, full length cDNA 2.3 kb) 
for a 559 aa polypeptide containing a conserved B9 domain (pfam07162.1). There 
are two other human proteins containing the conserved B9 domain. One is encoded 
by the EPBB9 (AB030506) gene on 17p and one by the LOC80776 (BC004157) 
sequence on 19q. However, the biological and molecular properties of the 
corresponding polypeptides are so far poorly understood.  All the three human 
segments that are coding peptides with B9 domains can be found from the list of the 
human orthologs for genes coding peptides in the flagellar (cilia in human) basal 
body proteome (Li et al., 2004). This would propose a role of the less characterized  
B9 protein domain in the human ciliary basal body proteome.  
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5.1 Mks1 gene expression in mouse embryo 
The mouse homologue of MKS1, the Mks1 gene locates in mouse syntenic MKS1 
locus on chromosome 11qC. This particular DNA region is well conserved between 
man and mouse both in gene content and order. We confirmed the structure of the 
previously unidentified mouse Mks1 gene (DQ177342) by sequencing the cDNA 
derived from mouse fibroblast cell line. Similarly to the human gene, the mouse 
gene was found to be composed of 18 exons. Mouse and human coding regions are 
86- 88% similar at the nucleotide level and 89% at the amino acid level.  
In situ hybridization detected ubiquitous Mks1 expression in mouse embryonic 
tissues at embryonic day 15.5. The prominent expression was detected in all the 
tissues which malformations are characteristic to MKS (Fig. 7). Intriguingly the 
strongest staining can be seen in the esophageal tract and in bronchioles of the lungs. 
 
 
Figure 7. In situ hybridization expression profile of Mks1 in mouse embryo. Sagittal 
sections of the whole embryo at embryonic day (E) 15.5 with antisense (a) and sense 
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(b) RNA probes. The expression of Mks1 is ubiquitous.  The expression is 
prominent in all the tissues which malformations characterize the disease phenotype: 
brain, kidney, liver and cartilage tissue of developing bone. A strong signal is 
detected also in the lungs. Higher magnification figures show expression in 
epithelial cells of the bronchiolus (arrows) and the staining is also prominent in the 
esophageal epithelium (arrow) (c); Front digits. Strong expression is seen in the 
cartilage tissue of the developing digits (d); Selected brain areas. Chp, choroid 
plexus. Mo, medulla oblongata. (e) Prominent signal is also seen from the neopallial 
cortex (arrow) (f); Cortical region of the kidney. Arrow is pointing the position of 
vertebra (g); Liver (h). Original magnifications: (a)-(b) 1x, (c)-(h) 20x. 
 
5.2 MKS1 is conserved among species 
Comparison of the MKS1 sequence across the species reveals high conservation (Fig. 
8). The MKS1 polypeptide identifies in the reciprocal blastp search only one result in 
C. elegans proteome identifying the xbx-7 gene (R148.1) that contains the X-box 
promoter element. This element is regulated by the transcription factor daf-19, which 
is a member of the RFX protein family and known to be required for cilia formation in 
C. elegans (Swoboda et al., 2000; Efimenko et al., 2005). Cilia and flagella are 
essentially identical organelles and highly conserved among species. A recent study 
used comparative genomics of human (having cilia), Chlamydomonas (having 
flagella) and Arabidopsis (lacking both) to identify genes specific for ciliary proteins 
and proposed that the MKS1 sequence would encode a polypeptide that is conserved in 
the flagellar (cilia in human) and basal body proteome (flagellar apparatus basal body 
proteome, FABB proteome) (Li et al., 2004; Keller et al., 2005). More specifically, the 
Chlamydomonas ortholog of the MKS1 gene has been suggested to encode a core 
structural component of the centriole (Keller et al., 2005). Two other Chlamydomonas 
orthologs in human are suggested to encode centriole components (POC, proteome of 
centriole). These genes are mutated in OFD1 (oral-facial-digital syndrome, MIM 
258860) and NPHP-4 (nephronophthisis-4, MIM 606966). The authors of the 
proteomic analysis of Chlamydomonas centrioles suggest that OFD1 and NPH-4 are 
basal body or centriole defects which lead to ciliary dysfunction (Keller et al., 2005). 
Both of these diseases share similar phenotypic features with MKS. 
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Figure 8. Comparison of human (DQ185029), mouse (CAI25723), zebrafish 
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(XP_707300), Drosophila (NP_572804) and C. elegans (NP_497669) MKS1 
orthologs using ClustalW1.8 (BCM) followed by Boxshade. The orthologs were 
identified in reciprocal blastp searches. Original publication III. 
 
Intriguingly, all three human genes (MKS1, LOC80776 and EPPB9) encoding 
polypeptides with B9 domains are listed in the FABB proteome genes and all worm 
orthologs (R148.1, Y38F2AL.2 and K03E6.4) for the human B9 proteins have X-
box promoter elements and are also both proposed to belong to the ciliary proteome 
based on comparative genomics and their exclusive expression in ciliated cells 
(Blacque et al., 2005).  
 
5.3 Putative cellular localization of MKS1  
Bioinformatics-based analysis (PSORTII) predicts cytoplasmic localization for the 
deduced MKS1 polypeptide. Our immunofluorescence analysis of transiently 
transfected HEK293 cells with the GFP-MKS1 agrees with the predicted 
cytoplasmic location of the peptide. To address the potential cilial localization of 
MKS1 polypeptide, we compared the in vitro expression pattern of the MKS1 with 
the immunostaining of polyglutamylated tubulin, a known molecular component of 
cilia (Bobinnec et al., 1998). Although there are problems associated with transient 
expression systems for intracellular localization studies, we could observe co-
localization of polyglutamylated tubulin and fluorescent MKS1 protein providing 
further support for the ciliopathy-character of MKS (data not shown).  
 
5.4 Discussion of the initial characterization of MKS1 
The identification of the MKS1 gene exposed a previously unknown human gene, 
which function is essential for the normal development of many tissue types and 
organs.  MKS1 is conserved among species which has greatly facilitated the initial 
characterization of its cellular role in ciliary and basal body proteome (FABB 
proteome) (Fig. 9).  
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Figure 9. The concept of the FABB proteome: 688 proteins in the flagellar 
apparatus basal body proteome. Venn diagram of the comparative approach to 
enrich for flagellar and basal body proteins. The proteome of Chlamydomonas 
(upper left) was compared to the proteome of human (upper right) by WU-BLASTP 
to find all the matches with a cutoff E value 10-10. These 4 348 matches were then 
compared to the proteome of Arabidopsis (below) by WU-BLASTP to remove all 
matches a cutoff E value of 10-18. The 688 proteins remaining are designated the 
FABB proteome (The middle overlapping section). Li et al., 2004.  The human 
MKS1 (FLJ20345) belongs to the FABB proteome.  
 
The 559 aa MKS1 peptide contains a conserved B9 domain, which cellular 
function is poorly understood. In the human proteome there are two other gene 
products with B9 domain, and moreover both of them belong to the suggested 
flagellar (ciliary) basal body proteome. In addition, the C.elegans´ orthologs for the 
human genes encoding B9 protein are known to have a binding site for the cilia 
specific transcription factor daf-19.  
We identified and characterized also the genomic structure of the well 
conserved mouse Mks1 gene, which is highly similar to human gene, and provides 
the possibility in future studies for targeted mutagenesis in this good model 
organism for mammalian organogenesis.  RNA in situ hybridization of Mks1 on the 
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mouse embryonic tissues (embryonic day 15.5) established the expression profile for 
the gene, which is congruent with the patients´ tissue phenotype.  Although the 
strong staining in the esophageal tract and lungs was highly unexpected. It is known 
that the epithels of the bronchioles in the lungs and esophageal tract are rich in cilia. 
Hypoplastic lungs are frequently reported in the patients, but this has generally been 
thought to be caused by the mechanical pressure of the vast kidneys and lack of 
amniotic fluid. Another important clinical observation is the increased risk of MKS 
patients for situs inversus totalis. It is known to be caused by dysfunction of the 
nodal cilia and thus supports the putative role of MKS1 in ciliogenesis. The cilia are 
known to be critical in signaling pathways which are involved in the early 
embryonic development. The genes encoding molecular components for the WNT 
and Hedgehog pathways were originally suggested to be excellent candidate genes 
for MKS. The mouse phenotypes with defects in Wnt signaling leads to 
hepatobiliary tract anomalies with cystic kidneys and respectively the defects in the 
Hh pathway causes CNS malformation seen together with dysmorphic limb buds 
(polydactyly). The current data demonstrate a functional structural role of the cilia in 
both signaling pathways critical for normal embryonic development, which agrees 
completely with the initial identification of the MKS1 peptide being a putative 
structural component of the cilia.  
 
6. LOCUS HETEROGENEITY IN FINNISH FAMILIES, MKS4 
We found the primary evidence of the further locus heterogeneity by analyzing a 
Finnish family with two MKS affected children and two healthy siblings. The 
affected siblings fulfilled the diagnostic criteria and no phenotypic differences were 
observed in the careful clinical examination to MKS patients linked to other MKS 
loci. The genealogical study revealed a consanguinity between the maternal 
grandmothers of the parents: six and seven generations back in the middle of the 18th 
century their ancestors lived in the same rural municipality and shared a rare family 
name, which is known to originate from the same household in 90 % of cases.  
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Originally in this family linkage was excluded to the three known MKS loci 
with distinct lack of cosegregation of the diseased haplotypes on MKS1, MKS2 and 
MKS3 loci.   
The genomescan with average 10 cM marker distance in our family showing 
exclusion to known MKS loci produced the maximum two point LOD scores (0.85) 
in six positions in the genome, which were all novel for MKS:   D9S1776 (9q33), 
D14S280 (14q32), D16S516 (16q23), D17S799 (17p12), D17S798 (17q11), 
D22S280 (22q12) and D22S283 (22q12). (Fig. 9a). Further the 10K SNP array 
(Affymetrix) revealed a multipoint LOD score of 3.6 (MAPMAKER/HOMOZ)  on 
9q33-34 agreeing with the maximum two point LOD score with STR marker 
D9S1776 (Fig. 9b). No other significant LOD scores were observed elsewhere in the 
genome in the analysis of the SNP genotypes. The 5 cM homozygous haplotype 
shared by the affected siblings on 9q was confirmed by genotyping a dense STR 
marker set covering this region with intermarker distance ≤ 500 kb.      
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Figure 9. a) Two point LOD scores (MLINK) in the family. The mean intermarker 
distance is 10 cM in the scan with multiallelic markers. The maximum LOD-score of 
0.85 (p<0.02) was obtained for six marker loci. None of them overlap any of the 
three previously established MKS loci. The chromosome 17q maximum LOD-score 
was obtained with marker D17S798 (17q11) that is distinct to MKS1 locus on 17q23. 
b) The multipoint LOD scores on chromosome 9q32-33.1 (HOMOZ/MAPMAKER). 
The microsatellite marker D9S1776 gets assigned on this region. The region of 
shared homozygosity in the MKS affected fetuses is flanked by the SNP markers: 
SNP_A-1508357-SNP_A-1510335 (positions on chromosome 9: 113527724-
118614930; USCS, May 2004).  We confirmed the shared homozygosity on this 
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chromosomal region by genotyping eight additional multiallelic markers (STR) with 
intermarker distance of 500 kb. Original publication IV. 
 
6.1 Novel locus on 9q 
The observed putative shared homozygosity by the affected fetuses with the 9q32-
33.1 SNP genotypes (MAPMAKER/HOMOZ) was confirmed by genotyping eight 
regional multiallelic markers. The longest region of shared homozygosity can be 
restricted between markers D9S1824 and SNP_A-1510335, which demarcate a 4.6 
Mb region on the basepair positions 113 971 790-118 614 930 (UCSC, May 2004) 
(Fig. 10). 
 Interestingly the identified MKS4 locus overlaps a novel Bardet Biedl 
syndrome locus (BBS10), which has been mapped in a consanguineous Bedouin 
family. The BBS in this Bedouin family is associated to a missense mutation in the 
TRIM32 gene. This finding is supported with additional functional data in a zebrafish 
model (Chiang et al., personal communication and abstract: ASHG meeting 2005). 
This gene is also associated to the autosomal recessive limb girdle muscular 
dystrophy type 2H (LGMD2H) (MIM 254110).  
 
Figure 10. The physical map of the critical chromosomal region on MKS4 locus on 
9q32-33.1 (UCSC May 2004; Refseq genes). The sequencing of the circled genes 
TNC and TRIM32 in the patients did not detect any potential pathogenic sequence 
alteration in the coding regions.   
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6.1.1 Candidate gene analysis on MKS4 locus 
There are 17 regional candidates on 9q32-33.1.  The most prominent candidates are 
TNC and TRIM32 genes based on the functional information available. TNC gene is 
also a human ortholog for the FABB proteome similarly to the MKS1 gene. TRIM32 
is associated to Bardet Biedl syndrome (Chiang et al., personal communication, 
ASHG 2005).  
The direct sequencing of TNC and TRIM32 coding regions in the two MKS 
affected siblings did not detect any potentially pathogenic sequence alterations. TRIM32 
is a gene coded by an intron of ASTN2 gene (Fig. 10), which is positionally an excellent 
candidate for MKS4 as well. We are currently analyzing this transcript in patients. 
 
6.2 Discussion of the observed locus heterogeneity and the MKS4 locus 
MKS shares characteristic clinical features with other disorders which are known to be 
caused by ciliary defects. Typical for these disorders are locus heterogeneity and the 
autosomally recessive inheritance mode. An excellent example being Bardet Biedl 
syndrome (BBS), which can be caused by mutations in a minimum of ten genes.  
We identified the fourth MKS gene locus to chromosome 9q32-33.1 in an 
inbred Finnish family. It is not known yet if all the 14 Finnish families in which we 
have not been able to detect coding region mutations in MKS1 gene, would be linked 
to chromosome 9q. Unfortunately most of these families are small in size and have 
only one affected child. Our initial haplotype analyses with multiallelic marker set 
with intermarkers distance 0.5 kb  in these families do not support the idea of a 
common founder mutation on chromosome 9q (Kyttälä et al., unpublished data). 
However, if the mutation is very old it is probable in theory that the marker density 
is not sufficient.  The final disease gene identification will confirm this. 
The MKS4 locus might provide a genetic link to MKS and BBS since one of 
the BBS genes (BBS10, Chiang et al., 2005 ASHG personal communication) has 
been mapped to this particular region, which is at the moment under investigation in 
the MKS patients.  
 89 
CONCLUDING REMARKS AND FUTURE PROSPECTS 
MKS1 is a novel human gene which mutations cause a severe multisymptomic 
embryonic developmental disorder, Meckel syndrome (MKS). The current data 
available from the conserved MKS1 orthologs as well as from other human diseases 
and animal models with ciliary defects all imply that MKS represents a novel 
ciliopathy. There are at least four genes which defects can cause MKS. The 
characterized human ciliopathies demonstrate locus heterogeneity suggesting that it 
is a typical feature for the disorders of ciliary origin. The same phenotype can be 
caused by defects in several molecular components implicated in the ciliogenesis 
and ciliary functions. To date there are four genetic loci identified in MKS and the 
future studies should demonstrate the true extent of the genetic heterogeneity. The 
identification of the disease genes and the extent of the locus heterogeneity will 
provide more accurate prenatal and preimplantation diagnosis for MKS families.  
MKS can not be cured, which makes the precise diagnosis important for the families 
with history of MKS. 
The existence of cilia had been almost ignored for decades, but during the past 
years the research on these cell organelles has shown their implications in many 
disease pathologies. MKS should serve as an excellent model to understand and 
study the role of ciliogenesis in the early embryonic development and provide 
information of its developmental role in very distinct type of tissues. The recent 
research data from Wnt and Hh signaling pathways have shown that they are both 
dependent on functional cilia, which would propose that the secondary effect in the 
cellular pathogenesis of MKS most likely leads to defects in these pathways.  
The loss of normal ciliary function in mammals is responsible for cystic and 
noncystic pathology in the kidney, liver, brain, and pancreas, as well as in severe 
developmental patterning abnormalities. However, the physiological role of cilia in 
most tissues remains obscure. The gene defects underlying in Bardet Biedl 
syndrome have proposed that ciliary functions may have roles also in more common 
human disorders such as hypertension, obesity and diabetes, thus making the 
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research on basal body and cilia highly meaningful also in this aspect. The MKS1 
gene will most likely provide general information of the ciliary functions that can be 
also essential in understanding these common human conditions currently under 
growing interest of pharmaceutical research to provide more specific and efficient 
therapeutic medication for these epidemics in the modern world.  Therefore the main 
challenges in the future functional studies will be to provide the information about 
the specific functional role of MKS1 and the other MKS gene products in basal body 
and ciliary proteome.  They are critical for the normal function of this cell organelle. 
The identification of the MKS1 gene proposes that the research on MKS genes 
should offer novel molecular level information for better understanding the 
physiological role of cilia in many tissue types in which it has not yet been 
recognized.  
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